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Abstract 
 
Type 2 diabetes (T2D) is a metabolic disease that results from complex interactions 
between the environment, the genetic variation and epigenetic regulation of gene 
expression in individuals.  Beta-cell dysfunction and insulin resistance are regarded 
as the hallmarks of the disease as the common presentation of T2D is the inability of 
beta-cells to adequately respond to the insulin demands of the body. The prevalence 
of T2D in Africa, and particularly South Africa, is on the rise. This is very likely the 
result of the combination of genetic susceptibility with increasing availability and 
accessibility of relatively cheap, highly palatable, calorie-dense meals with no 
corresponding lifestyle adjustment.  
This study aims to utilize available data from GWAS and gene expression arrays to 
identify potential variants that likely influence T2D susceptibility in African 
populations. Two public data repositories were mined – the National Center for 
Biotechnology Information’s (NCBI)  Gene Expression Omnibus (GEO) and the 
National Human Genome Research Institute’s (NHGRI) GWAS Catalog. The criteria 
for selecting the studies for inclusion were based on ten descriptive T2D-related 
terms taken from the GWAS catalog’s pre-defined search categories. These terms 
were also  applied to the selection of gene expression studies in GEO. These terms 
are: “fasting glucose-related traits”, “fasting insulin-related traits”, “fasting plasma 
glucose”, “insulin resistance/response”, “insulin traits”, “diabetes-related insulin 
traits”, “pro insulin levels” “Type 2 diabetes”, “type 2 diabetes and 6 quantitative 
traits” and “type 2 diabetes and other traits”. Ten Affymetrix platform-based studies in 
human tissues were chosen from GEO using these criteria. A Benjamini-Hochberg 
adjusted p-value of 0.05 was set as a cut-off for significant differentially expressed 
genes (7,887 genes) with 497 genes  occurring in two or more studies, based on 
tissue- or array-type, considered candidates for downstream analysis. The GWAS 
catalog presented 175 “reported” genes and 218 SNPs from 51 studies matching the 
set T2D-related criteria. 
Functional analyses done with the Database for Annotation, Visualization and 
Integrated Discovery (DAVID) on both the GWAS and expression studies genes lists, 
with similar parameters, provided enriched gene lists. The union of both lists gave a 
core list of 140 genes for further analyses. These genes were used to retrieve 
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corresponding SNPs from the 1000 Genomes data set. The choice of this database 
stems from the presence of whole genome sequence data, albeit relatively low 
coverage (4X – 6X), of individuals in several populations on different continents. The 
populations of interest in this study, however, were the LWK (Luhya in Webuye, 
Kenya), YRI (Yoruba in Ibadan, Nigeria), CEU (Utah Residents with Northern and 
Western European ancestry), TSI (Toscani in Italia), CHB (Han Chinese in Beijing, 
China) and JPT (Japanese in Tokyo, Japan). The choice of these populations as 
proxies for each of the three continents was based on data availability in this version 
of the 1000 genomes data. Assessing the distribution of the risk allele frequencies of 
the GWAS SNPs across these populations showed the risk of T2D to be highest in 
the African populations. Intercontinental comparisons of SNPs provided a means to 
identify possible variations in SNP frequencies and occurrences between 
populations. 
 
Fixation indices (FST) analysis was done on pairwise combinations of each African 
population with a non-African population resulting in 6 pairwise comparisons. These 
comparisons were combined by continent with the intersecting SNPs across 
continents providing the African vs non-African comparison, which is the main focus 
of this study. FST analysis produced a list of 7 genes (Notch homolog 2 (NOTCH2), 
Kinesin Family member 11 (KIF11), Nuclear Receptor Subfamily 2 (NR2F2), 
Ribosomal Protein L35A (RPL35A), Small Nuclear Ribonucleoprotein D1 
Polypeptide 16kDa (SNRPD1), RNA Guanylyltransferase And 5'-Phosphatase 
(RNGTT), expression analysis and RNA binding motif protein 38 (RBM38)) from 228 
SNPs showing significant differentiation between the African continent and 
European/Asian continents. The integrated haplotype score (iHS) was used to 
identify possible signatures of selection in the LWK and YRI populations. One of 
these seven genes, SNRPD1, was also selected, based on iHS results. Its 
involvement has been proposed in the spliceosome pathway and the RNA splicing 
process. Interestingly, it has not been shown to be associated with T2D in existing 
literature. 
 
The identification of specific variants in T2D susceptibility genes in Africans will not 
only contribute towards a knowledgebase that will be useful for developing 
genotyping arrays that better represent African enriched variants, but also very likely 
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give some insight into the missing heritability component of the pathogenesis of the 
disease. Such knowledge will, in the long-term, lead to better targeted therapeutics 
for managing T2D. 
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1. CHAPTER ONE – INTRODUCTION 
1.1 Pathophysiology of Type 2 Diabetes (T2D) 
Type 2 diabetes (T2D) is a complex disorder of multiple interactions between the 
environment and genetics, with metabolic implications. Although its aetiology is not 
fully understood, it is known to be characterized by the failure of the body to respond 
normally to insulin, and the inability of the body to compensate for this condition to 
maintain euglycaemia. The failure of the pancreatic beta-cells to adequately respond 
to an increased demand for insulin manifests clinically as elevated postprandial 
blood glucose and fasting levels which are some of the diagnostic criteria for T2D [1–
3]. T2D is very often correlated with obesity. Despite this high correlation, obesity, a 
major confounder in T2D, does not necessarily result in T2D as studies have shown 
that ~10% of individuals with T2D are neither obese nor overweight [4]. It is also 
important to note that not all obese individuals become diabetic. Those who become 
diabetic have beta cells that are unable to maintain high insulin output to overcome 
the resistance, with beta cell failure then leading to diabetes. Non-obese type 2 
diabetics tend to have beta-cell dysfunction but not necessarily insulin resistance, 
whereas obese T2D individuals are  both insulin resistant and have reduced insulin 
secretory output [5], highlighting the problem of dysfunctional insulin response. 
It has also been proposed that low birth weight owing to in utero nutritional 
deprivation influences susceptibility to obesity, T2D and other metabolic conditions 
later in life through the acquisition of a ‘thrifty phenotype’ [6]. The thrifty phenotype 
hypothesis suggests that fetal and infant malnutrition, and consequently poor growth 
result in permanent changes in glucose-insulin mechanism [6]. Some of these 
changes are reduced insulin secretion capacity and insulin resistance, which when 
combined with other risk factors like obesity, physical inactivity and ageing are 
critical in the development of T2D [6]. This association between poor fetal and infant 
nutrition and weight  with obesity and T2D first highlighted by Hales and Barker [7] 
has been demonstrated in  several studies including the Chinese Famine (1959 – 
1961) Study [8] and the Dutch Hunger Famine birth cohort study [9].   
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1.1.1 Insulin Resistance 
Insulin resistance is a physiological state where the cells in the body respond 
abnormally to the actions of the insulin hormone. It can result from several factors 
including increased levels of adipocyte-derived free fatty acids. This can inhibit 
insulin-dependent glucose uptake and lead to reduced glucose utilisation and 
oxidation in the muscle [10]. However, the main cause of insulin resistance is 
obesity. Other contributors to insulin resistance are adipokines. Adipokines are 
proteins produced and secreted by adipocytes [11]. These include interleukin-6 (IL-
6), tumor necrosis factor alpha (TNF-α) and adiponectin. In obesity, the expression 
of IL-6 and TNF-α is increased while adiponectin is under expressed. Studies have 
suggested that IL-6 produced by visceral adipose tissue can directly affect hepatic 
metabolism as its venous drainage goes directly through the portal vein to the liver, 
making it possible for IL-6 to contribute to triglyceridaemia by its stimulation of the 
hepatic secretion of very low density lipoprotein [12]. TNF-α is a pro-inflammatory 
cytokine that is involved in the pathophysiology of insulin resistance possibly through 
the mechanism of interfering with the phosphorylation of the insulin receptor 
substrate (IRS-1) [13]. Studies have also shown adiponectin to augment lipid 
oxidation in the skeletal muscle and to reduce hepatic glucose production in the liver 
[14, 15] and to increase whole body insulin insensitivity. An increased lipid oxidation 
implies less ectopic fat deposition that can also aggravate insulin resistance [16]. 
Obesity can lead to insulin resistance not only by increased adipokine levels but also 
by increased ectopic fat deposition in the skeletal muscle which could lead to 
hyperglycaemia. It is also possible that sedentary lifestyle habits and unhealthy diet 
could serve as initiators of a cascade of events leading to the development of insulin 
resistance [17].  
1.1.2 Beta-cell Failure 
The inability of existing pancreatic beta-cells to either increase insulin secretion or 
proliferate to compensate for the increased insulin need resulting from a situation of 
insulin resistance is regarded as a condition of beta-cell dysfunction.  The exact 
mechanism of beta-cell failure in T2D is controversial [18], but it has been proposed 
that the endocrine islet’s homeostatic function is poor and unable to cope with 
environmental or metabolic stressors such as obesity, ageing and pregnancy where 
levels of insulin resistance are known to increase [19]. This is because the manner of 
physiological adaptation of beta-cell functions to conditions like ageing and 
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pregnancy which is mainly achieved through the modulation of beta-cell replication is 
very taxing for pre-diabetic beta cells [20]. Another widely believed explanation for 
beta cell dysfunction is that the stress imposed on the beta-cells to increase insulin 
production to allow for glucose clearance from the blood wears out the cells and 
eventually lead to cell death which reduces the number of beta-cells producing 
insulin and consequently results in insufficient insulin production. Another 
explanation, originating from mouse models [20] is that these beta-cells do not 
necessarily die (loss of cells) but dedifferentiate to the original progenitor cell form 
[21] (loss of function) and require the correct molecular signals to be re-differentiated 
back to adult insulin-producing beta-cells.  
Clarity on the mechanism of beta-cell dysfunction as well as insulin resistance will 
very likely provide more insight into the pathogenesis of the disease and possibly 
therapeutic solutions as these conditions are central to the development of T2D.  
Figure 1.1 shows a proposed schema for the pathogenesis of T2D. 
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Figure 1.1 A proposed schema for the pathogenesis of T2D.  
Interactions between environmental and genetic factors contribute to the processes 
involved in T2D with some of the genes and exposures shown in yellow. FTO = fat 
mass and obesity associated gene. PPARG = peroxisomal proliferator-activated 
receptor-g. CDKAL1 = CDK5 regulatory subunit associated protein 1-like 1. KCNJ11 
= potassium inward rectifying channel, subfamily J, member 11. [22] 
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1.2 Epidemiology of the Disease 
Despite the seemingly long history of T2D worldwide, it has only been recently 
identified as a major problem on the African continent. This can be attributed to the 
increasing industrialisation and acculturation [23] in Africa, with high caloric diets 
replacing the high fibre diets and no corresponding lifestyle adjustments. The 
research efforts have not been as extensive as they have been in infectious 
diseases like HIV/AIDS, malaria, diarrhoea, respiratory infections and tuberculosis, 
which according to current statistics, account for the majority of the morbidity and 
mortality on the continent [24]. Recent projections, however, indicate that the 
morbidity and mortality rate of non-communicable diseases like T2D and 
cardiovascular disease, a T2D comorbidity, will soon exceed those of the infectious 
diseases [24]. With the rapidly increasing burden of the disease, it is imperative to 
accelerate research efforts in the field. 
1.2.1 Worldwide Prevalence and the Increasing African Burden 
In a global study to estimate the prevalence of diabetes across all age-groups for the 
years 2000 and 2030, an increase of over 110% in the total number of people 
worldwide was predicted in the 30-year period [25]. The prediction for the prevalence 
of diabetes in that same period in sub-Saharan Africa is a projected rise from 7.2 
million in the year 2000 to 18.7 million in 2030 [25]. This represents a massive 161% 
increase in the proportion of individuals with diabetes, which is about a 50% 
difference from global predictions. This study, however, acknowledged that these 
numbers most likely underestimate the future prevalence of diabetes as the 
incidence of obesity continues to rise [25]. The 6th edition of the International 
Diabetes Foundation (IDF) predicts a rise from 382 million people with diabetes in 
2013 to 592 million people by 2035 globally (figure 1.2), 80% of whom live in low- 
and middle-income countries [26]. Interestingly, about 90% of all diabetic cases 
reported are T2D [27]. The remaining ~10% include (but is not limited to) Type I 
Diabetes (T1D), Gestational Diabetes (GDM), Maturity Onset Diabetes of the Young 
(MODY) and Ketosis-Prone Diabetes (KPD). T1D is an autoimmune disease where 
the insulin-producing cells in the pancreas are attacked by the defence system of the 
body [28]. GDM is a condition of high glucose levels in the blood that occurs during 
pregnancy. It is defined as any degree of glucose intolerance with onset or first 
recognition during pregnancy [29]. Although a temporary condition, the risk of 
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developing T2D later on has been shown to be higher in women who have had GDM 
compared to those who have not [30]. MODY, often referred to as monogenic 
diabetes [31], is a hereditary form of diabetes that presents itself in multiple forms. It 
results from mutations in an autosomal dominant gene that interferes with the 
production of insulin. KPD is a rather unique form of diabetes as it has been known 
to affect only individuals of non-Caucasian ethnicity [32]. It is regarded as a 
heterogeneous disease characterised by presentation with diabetic ketoacidosis 
(DKA) in individuals who do not necessarily fit the typical characteristics of other 
traditional diabetic categories as defined by the American Diabetes Association 
(ADA) [33]. However, T1D and T2D patients have been known to present DKA under 
infection or stress conditions [34]. Interestingly, in all of these forms of diabetes, the 
treatment course almost always ends in insulin therapy. 
Figure 1.3 shows the worldwide distribution of the number of people with diabetes in 
2013.The prevalence statistics of diabetes in 2013 can be seen in figure 1.4 while 
figure 1.5 shows the percentage of diabetes-related deaths in individuals below the 
age of 60 in that same year. 
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Figure 1.2 IDF global predictions for diabetes incidence increase between 2013 and 
2035.  
AFR = Africa, MENA=Middle East and North Africa, SEA = South East Asia, SACA = 
South And Central America, WP = Western Pacific, NAC = North America and 
Caribbean, EUR = Europe [26]. 
 
Figure 1.3 Global distribution of people (in millions) with diabetes in 2013 [26]. 
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Figure 1.4 Global prevalence of diabetes (%) in 2013 [26].  
 
 
Figure 1.5 Global percentages of diabetes-related mortalities in 2013 [26]. 
The mortality rates shown in figure 1.5 are highest in Africa even though the 
continent had the lowest prevalence percentage. This again points out the need for 
more African-focused research efforts as the burden of the disease on the African 
continent is increasing greatly. Just like it has unravelled in more developed 
economies, the increasing prevalence of obesity on the continent is leading to a 
diabetes epidemic. Age-specific data have also indicated an increase in diabetes 
rate with age in sub-Saharan Africa [35, 36].  
Obesity, nonetheless, remains a major risk factor to the development and 
pathogenesis of T2D. It generally occurs as a consequence of an imbalance 
9 
 
between energy intake and expenditure that is usually characterized by increased fat 
storage [37]. It results chiefly from a combination of genetics, low level of physical 
activity, and an environment where relatively cheap, highly palatable, calorie-rich 
food is widely available [38, 39]. It is therefore not surprising that the number of 
obese or overweight people now exceeds the underweight population worldwide 
[40]. However, the concept of metabolic obesity (the existence of the metabolic 
profile associated with obesity in non-obese subjects) which is the result of the 
accumulation of fat in the abdominal viscera in non- obese individuals [41], has been 
proposed to possibly provide an explanation for high T2D incidences in populations 
with seemingly normal weight individuals [42].  Asian individuals tend to develop T2D 
at lower body mass index (BMI) levels than Europeans [43] and the risk of 
developing T2D is generally higher in Asians than in Europeans [44] despite the 
mostly lower prevalence of overweight or obese individuals in Asian populations. 
Studies have shown Asians to be more likely to have a higher fat percentage or 
visceral adiposity than Europeans at a given BMI or waist circumference [45, 46]. 
Waist circumference is a measure of central adiposity. Measures of central adiposity 
have been shown to be better indicators of T2D risk than BMI [44]. 
An obesity pandemic is a prelude to increased prevalence of T2D and other non-
communicable diseases, as type 2 diabetics are at a high risk of developing a range 
of disabling conditions like hypertension, stroke, renal failure and cardiovascular 
disease (CVD) [4]. It is of little surprise then that the prevalence of diabetes and CVD 
is on the rise in Africa as obesity levels increase across the continent. 
It is important to note that in addition to the changing physical activity levels and diet, 
ongoing demographic changes like urbanization as well as political and economic 
instability contribute considerably to the burden of diabetes and other non-
communicable diseases on the African continent [24]. 
1.2.2 Comorbidities and Complications 
As has been previously indicated, the comorbid conditions and complications of T2D 
contribute to the burden of the disease. Some comorbidities and complications of 
T2D include hypertension, dyslipidemia, stroke, microvascular diseases (renal 
failure, neuropathy, and retinopathy) and CVD. Stroke is, more often than not, a 
consequence of CVD, and CVD results from complex interactions between genetic 
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and environmental factors together with high risk factors like diabetes and 
hypertension [47]. It is the most common cause of death globally [24] and, as is 
stated in the previous section, is increasing in prevalence in tandem with T2D. 
Diabetic neuropathy results from damage to the nerves as a result of high blood 
pressure and high glucose levels with the most commonly affected areas being the 
extremities particularly the feet. Similarly, diabetic retinopathy and nephropathy 
(kidney failure) can be caused by consistently high blood sugar levels together with 
high cholesterol and high blood pressure [48, 49]. The consequence of this in 
nephropathy is the damage to the tiny vessels in the kidneys that serve as waste 
filters from the blood which implies inefficient functioning of the kidneys or in some 
cases, total failure. In retinopathy, the blood vessels of the retina are damaged which 
may potentially lead to blindness. The risk for other vision-affecting conditions like 
cataracts and glaucoma is also increased in T2D [48, 49]. The microvascular 
diseases are generally linked to hyperglycemic conditions with hyperglycemia-
induced abnormalities in the hexosamine, polyol and protein kinase C pathways 
having been implicated in the mediation of tissue damage in T2D [50, 51] 
Hypertension is a chronic condition of elevated blood pressure. About 75% of 
individuals with T2D also have hypertension and those with hypertension on its own 
show indications of insulin resistance [52]. The risk factors and complications of 
hypertension overlap significantly with those of T2D [53] which in some cases of 
CVD could result from the continuous strain imposed on the heart by elevated blood 
pressure. 
Dyslipidemia is a condition that can result from prolonged increased insulin levels in 
the blood which can cause insulin resistance and consequently free fatty acid flux 
from the insulin resistant adipocytes [54–56]. It thus makes logical sense that in T2D, 
the phenotype associated with dyslipidemia is mainly attributed to insulin resistance 
and insulin deficiency [57, 58]. This phenotype generally presents 3 characteristic 
features – low HDL cholesterol concentration, increased concentration of small 
dense LDL cholesterol particles and high plasma triglyceride concentration. T2D is 
not only an independent risk factor for CVD, it also amplifies the effects of other 
common risk factors like hypertension and smoking. Dyslipidemia in T2D contributes 
to the risk of the development of CVD. 
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Although some of these complications could be disabling and even life-threatening, 
they could be stalled by good management of the disease, which includes proper 
glucose levels monitoring.  
The complications and comorbidities associated with T2D not only complicate the 
management of the disease but also make it a multi-faceted challenge with an 
enormous burden on an already over-tasked healthcare system. 
1.3 Genomic Contributions to Type 2 Diabetes 
Global T2D research efforts have been able to identify a number of genetic variants 
with risk associations to the disease. A recent review showed variants in about 60 
genes to have significant associations with the development and pathogenesis of 
T2D [59]. However, this list excluded genes like potassium inward rectifying channel, 
subfamily J, member 11, KCNJ11 and calpain 10, CAPN10 – genes identified in 
candidate gene analyses and family-based linkage studies. Some of the confirmed 
risk variants include rs7903146 (transcription factor 7-like 2, TCF7L2), rs12255372 
(TCF7L2), rs1111875 (hematopoietically expressed homeobox, HHEX), rs5215 
(KCNJ11), rs9939609 (fat mass and obesity associated gene, FTO) and rs1801282 
(peroxisomal proliferator-activated receptor-g, PPARG) [60].  Studies have indicated, 
however, that all the risk variants together account for only about 10% of the genetic 
contribution to the disease [61, 62]. T2D concordance ranges between 30% and 
80% as have been shown in monozygous twin studies and heritability of the disease 
has been indicated at 30-70% in family studies [57, 63]. 
The bulk of T2D research has been done in non-African populations. With the 
knowledge that T2D has a strong genetic component, albeit not entirely resolved, it 
is expected that there exists a considerable ethnic variation in the prevalence of the 
disease [50]. The specificity of a locus in the HHEX gene in conferring T2D risk in 
East Asians [64] demonstrates, to an extent, this ethnic-specificity. A few notable 
studies carried out in populations in West Africa and of West-African or African 
origin, in the United States, have identified gene variants and significant linkages in 
regions previously identified as T2D susceptibility loci in other populations [65]. The 
Africa America Diabetes Mellitus (AADM) Study [65], the longest running genetic 
epidemiological T2D study that involves Africans, included West African participants 
whose data have been included as a replication cohort in several genome-wide 
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association studies (GWAS). One such collaborations led to the observation that 
prostate cancer risk variants, rs4430796 and rs757210, in the transcription factor 2, 
TCF2 (also known as hepatocyte nuclear factor 1 beta, HNF1B) gene confer 
protection against T2D [66]. Collaborations with deCODE Genetics elucidated the 
impact of recent selection in the TCF7L2 gene in relation to T2D risk [67] and 
confirmed genome-wide significant associations of CDK5 regulatory subunit 
associated protein 1-like 1, CDKAL1 variants in T2D susceptibility [68]. TCF7L2 has 
produced one of the strongest signals and most widely reproduced associations with 
T2D risk in several ethnic groups [69], including Africans as the deCODE-AADM 
collaboration showed. 
However, no GWAS has been conducted on T2D among populations on the African 
continent as of yet [24]. This creates a gap in our knowledge that needs to be 
bridged as the diverse nature of African populations could provide unprecedented 
insight into the missing heritability of T2D as some variants might be more relevant 
and therefore easier to pick up in cohorts of non-European ancestry. Also, since 
most of the current genome-wide study approaches are best suited to the 
identification of common variants, it has been speculated that rare variants could 
perhaps provide some more insight into the missing heritability component [59].  
1.4 Study Approaches to Identifying Genomic Contributions to the 
Aetiology of Complex Traits 
Like in many complex diseases, the global research trend in the genetics of T2D has 
gone through 3 main phases: family-linkage analysis and candidate-gene studies, 
association analysis and genome-wide association studies (GWAS) [2]. In addition, 
computational approaches, copy number variation (CNV) analysis, sequencing 
approaches, epigenetic methods as well as microarray gene expression analysis, an 
experimental approach based on wet lab experiments and subsequent 
computational analysis, have been used to prioritize candidate genes and pathways 
in complex diseases [70, 71] 
1.4.1 Linkage/Association Analysis 
Linkage analysis presents researchers with a method to map the location of disease-
causing genes by the identification of genetic markers that are co-inherited with the 
phenotype of interest. This means that a marker that co-segregates with a gene of 
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interest could be used to track the gene within a family without prior knowledge of 
the mutation as long as it is absent in unaffected family members.  It thus relies on 
matching of the disease with genetic markers of known location [2]. This method was 
effective in identifying genes in monogenic forms of the disease but not necessarily 
the complex form of the disease as it has had limited success as a result of weak 
genotype-phenotype association which is a hallmark of complex multifactorial 
diseases [72].  
Association analysis evolved to improve on simple family linkage analysis. This 
fundamentally more powerful method of susceptibility gene discovery depends on 
robust correlations of the allele frequencies of the genetic variants to the disease [2]. 
Most genetic association studies examined a single variation or a set of 
polymorphisms near a single gene or focused on a region defined by a linkage peak 
determined by a family study [73]. A major challenge with this method is that the 
causal variant itself or a marker to which it is tightly correlated has to be directly 
examined for a signal to be detected. This means that attention had to be directed to 
specific genes or variants of interest, some of which may have been inappropriate 
candidates [74]. Despite the low power of these methods, genuine susceptibility 
variants were discovered over the course of several studies. Some of these include 
CAPN10 [75, 76] and KCNJ11 [77]. 
1.4.2 Candidate Gene Studies 
This approach focuses on genes that have been selected for study based on the 
biological characteristics of the phenotype of interest and a supposed match 
between the presumed or known functions of the genes [2]. It is pretty much an 
association study that directly tests the effects of genetic variants of a potentially 
contributing gene [78]. Candidate gene studies, therefore, limit the number of tests 
for variant association to a small subset of the genome and focus hypotheses on 
sets of genes that are believed to be associated with the phenotype of interest based 
on prior knowledge [73].  
1.4.3 Genome-wide Association Studies (GWAS) 
Genome wide association studies (GWAS) have proven to be very successful in 
gene and gene variant identification owing largely to the fact that the entire genome 
is queried at once. It involves systematic, large-scale searches for statistically 
significant associations between disease and specific DNA sequence variants (e.g. 
14 
 
single nucleotide polymorphisms (SNPs)) [2] by querying for differences between 
affected and unaffected groups. GWAS has been especially successful in elucidating 
genetic variants that influence T2D and BMI with several GWAS confirming that a 
variant in TCF7L2 gene confers risk for T2D, while a variant in the FTO gene confers 
risk for obesity/BMI [59]. An advantage of GWAS over the other methods is its 
unbiased approach. Prior knowledge or hypotheses of associated genes or SNPs to 
the phenotype of interest is not necessary as the whole genome is being 
interrogated at once. A caveat then is the low power to definitively identify 
associations with such large number of tests being performed [73]. However, large 
sample sizes, often more than 10000 cases and controls compensate to increase the 
power to detect low to moderate effects. Most of the T2D-associated variants to date 
have been identified via GWAS. 
1.4.4 Copy Number Analysis 
Copy number analysis generally refers to methods of detecting copy number 
variation (CNV) from analysing data resulting from a queried DNA sample. Copy 
number variations are structural variations that are genomic DNA modifications that 
result in either functional or neutral variations in the number of copies of certain 
sections of the DNA. They usually correspond to relatively large deletions or 
duplications of genomic regions on certain chromosomes. CNVs can range from 1 
kilobase to several megabases and have been reported to account for about 12% of 
the genome making their role in disease aetiology possibly significant [79].  CNVs 
can contribute to disease susceptibility by influencing the gene expression level [80]. 
Genome-wide association analysis using a logistic regression model was used to 
assess disease susceptibility loci for risk of T2D in a Korean population [81]. This 
study identified 3 new CNV regions to be significantly associated to the disease. 
Also, T2D-associated CNVs have been reported in the leptin receptor, LEPR, a gene 
that has been implicated in obesity and diabetes, from genome-wide SNP chip data 
using the quantitative multiplex polymerase chain reaction of short fluorescent 
fragment (QMPSF) method[82] 
1.4.5 Epigenetics Methods 
Epigenetics generally refers to changes in gene expression that result from 
chromatin structure changes that do not alter the DNA sequence. These are 
heritable changes that can occur throughout developmental stages as well as in 
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response to environmental factors [83]. One  mechanism of epigenetic modification 
is the methylation of DNA. Modifications resulting from DNA methylation or histone 
modification alter chromatin structure (histone modification) which can in turn alter 
transcription patterns as a result of reduced gene accessibility to the components of 
the transcription machinery [84, 85]. 
DNA methylation is the tagging of DNA by a methyl group, usually from dietary 
sources, which can activate or repress the expression of genes. Methylation tends to 
occur primarily at CpG sites. A study examining genotypic-epigenotypic interactions 
in T2D that focused on previously known genomic susceptibility regions identified a 
risk allele in the FTO locus [86]. Also, individuals prenatally exposed to famine have 
been shown to harbour differentially methylated regions of genes of relevance to 
T2D [87]. An epigenomic approach thus contributes towards providing insight into 
the epigenetic and environmental factors that play roles in elucidating the aetiology 
of T2D. 
1.4.6 Sequencing and Computational/Bioinformatics Approach 
The development of parallel sequencing technologies has greatly expedited the 
discovery of human variations on a massive scale. This has been facilitated by the 
ability of next generation sequencing, NGS, technologies to relatively rapidly 
sequence entire individual genomes (whole genome sequencing, WGS) or just the 
coding regions of the genomes (whole exome sequencing, WES) [88, 89] The 
analyses of the resulting sequencing data can be potentially bioinformatics-intensive 
involving several computational steps and analyses pipelines. However, WGS and 
WES have been very useful in the identification of de novo mutations which include 
single nucleotide variations as well as short insertions and deletions (indels) in 
various complex diseases [90–94].  Several risk variants for T2D susceptibility in 
individuals of different ancestries have been identified via NGS technologies. Some 
of these include variants in the Early Endosome Antigen 1, EEA1, [95]. 
 Computational approaches to elucidating the pathogenesis of T2D have also led to 
the prioritization of some candidate genes like lipoprotein lipase, LPL and Enoyl CoA 
Hydratase, Short Chain, 1, ECHS1, both involved in fatty acid metabolism [70].. 
Other bioinformatics approaches include the meta-analyses and integration of data 
from either homogenous or heterogeneous sources. The general idea behind this 
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approach is to utilize the huge body of available study data with the help of 
bioinformatics tools to provide possible insights into the disease via the identification 
of risk-associated variants. Some of these sources include results from microarray 
expression studies, GWAS, linkage studies, interaction screens and disease 
similarity, gene ontologies and pathways databases [96, 97].  Meta-analyses 
approaches are sometimes used to augment low to moderately powered GWA 
studies to present statistically valid results. These methods generally involve the 
building of an interaction network or evidence layers based on the different data 
sources  with genes being subsequently ranked and prioritized based on statistically-
determined criteria [97]. The ability to reuse and reanalyse data in an integrative 
manner makes bioinformatics approaches critical in the elucidation of the 
pathogenesis of complex diseases. 
1.4.7 Rationale for Study Approach 
Genome-wide association studies have identified more T2D-susceptibility variants 
than any other approach prior to its inception. The idea of a GWAS on the African 
continent would thus be ideal in the search for possible African-specific T2D risk 
variants but this is not the objective of this project.  It is anticipated that the use of 
bioinformatics tools and methods to interrogate existing non-African-focused T2D 
studies, while analysing the results in the context of African population genetic 
variation via a database with whole genome sequence information from a number of 
African populations, would not necessarily identify novel genes but help to identify 
some novel risk variants for T2D that are important African contributors to the 
disease. Research efforts in T2D already indicate quite clearly that susceptibility 
variants vary across ethnicities as has been previously mentioned with the TCF7L2 
gene. It has been shown that the risk variants in this gene, although present in the 
Japanese and Chinese populations, do not confer the greatest risk to date in these 
populations as they do in Europeans - variants in the KCNQ1 do that [98, 99]. Also, 
T2D risk variants in the HHEX have been indicated to show specificity to East Asian 
populations [64]. Similarly, variants (rs1800963, rs1028583, and rs3818247) in the 
hepatocyte nuclear factor 4 alpha, (HNF4A), region  which show T2D association in 
the Finnish population do not show such association in the Ashkenazi Jewish 
population even though other SNPs (rs4810424 and rs1884614) in the HNF4A 
region show similar association levels with diabetes in both populations [100, 101]. 
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1.5 Study Aim and Objectives 
This study is based on the hypothesis that genetic variants in already identified 
genes that contribute to T2D susceptibility differ between Africans and non-Africans 
(Europeans and Asians). The objective is to use a bioinformatics approach to identify 
genetic variants that are likely to contribute to T2D susceptibility in African 
populations.  
1.5.1 Aim  
To mine public domain data for genes and genetic variants associated with T2D, and 
to combine this with differential gene expression data, in order to facilitate the 
identification of T2D risk elements and to make comparisons between Africans and 
non-Africans, using a bioinformatics approach. 
1.5.2 Objectives 
i. To generate a list of genes and gene variants that have been previously 
identified to be associated with T2D and its relevant associated traits in 
genome-wide association studies. 
  
ii. To assess the risk allele frequencies from the associated GWAS variants 
(SNPs) across populations. 
 
iii. To perform functional enrichment on the GWAS gene list to retrieve highly-
ranked genes for further analyses. 
 
iv. To augment the GWAS-generated gene list with a functionally-enriched list 
of genes that have been previously identified in T2D and its relevant 
associated traits in microarray-based gene expression studies. 
 
v. To analyse the augmented gene list in the context of African population 
genetic diversity to identify common and unique T2D risk variants. 
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2 CHAPTER TWO – METHODS  
An overview/workflow for this research is shown in figure 2.1 below. 
 
*Study selection criteria: 
 
Non-redundant Core Genes List 
GWAS SNPs List 
1000 Genomes 
Data 
Identify SNPs associated with genes  
List of highly relevant SNPs and their 
associated genes with possible association to 
T2D-susceptibility in Africans 
Population (allele) Frequency Analyses – FST and iHS 
Meta-analyses 
GWAS Genes 
List  
Expression 
Genes List 
Public data mining 
GWAS 
Studies*  
Expression 
Studies*  
Terms and Pathways 
(Bonferroni-adjusted P ≤ 0.05) 
Functional Analysis/Selection 
of Genes (DAVID) 
Functional Analysis/Selection 
of Genes (DAVID) 
Terms and Pathways 
(Bonferroni-adjusted P ≤ 0.05) 
T2D Risk Allele 
Population 
Frequencies 
• Diabetes-related insulin traits 
• Pro insulin levels 
• Type 2 diabetes 
• Type 2 diabetes and 6 quantitative traits 
• Type 2 diabetes and other traits 
 
• Fasting glucose-related traits 
• Fasting insulin-related traits 
• Fasting plasma glucose 
• Insulin resistance/response 
• Insulin traits 
 
Figure 2.1. Research workflow. 
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2.1 Public Data Mining and Pre-processing 
The retrieval of data from the public domain was done at two points – T2D-
associated study data and SNP data. 
 
2.1.1 T2D-associated Studies 
Two types of publicly available T2D-associated data were used in this study: 
Genome Wide Association Studies (GWAS) data and gene expression studies data. 
The GWAS catalog, a resource from the National Human Genome Research 
Institute (NHGRI), was used as the primary resource for GWAS data in this study. It 
is a manually curated collection of published association studies identified from 
several sources including PubMed, NIH-distributed compilations of news and media 
reports, as well as from comparisons with HuGE Navigator [102], an online 
repository of published epidemiology literature [103, 104]. This catalogue is available 
for direct online query as well as for downloads for offline queries. The studies 
included in this catalogue attempted to assay at least 100,000 SNPs in the initial 
design and exclude studies in languages other than English. Information extracted 
from these studies by the catalog curators include the initial and replication sample 
sizes, strongest SNP/trait association in the study (“SNPs”) as well as the risk allele 
if available (“Strongest SNP-Risk Allele”) and the genes associated with the 
strongest SNP/trait association (“Reported Gene(s)”). For each SNP that was 
identified for inclusion in the catalog, chromosomal regions were extracted from the 
UCSC Genome Browser [105]. SNP association p-values, odds ratios (“OR or beta”) 
and 95% confidence intervals (“95% CI (text)”) were also reported. In the absence of 
a combined p-value in the study report, the p-value and effect-size from the largest 
sample size is reported if the initial and replication samples each show SNPs/trait 
associations that meet the threshold of p < 10-5. The GWAS catalog generally does 
not include candidate gene-focused studies and SNP-trait associations with P > 1.0 x 
10-5. This relatively liberal statistical threshold was chosen to accommodate GWAS 
scans of different sizes while using a consistent approach, and to allow for the 
possible examination of marginal associations [103, 104]. 
 
The National Center for Biotechnology Information’s (NCBI) Gene Expression 
Omnibus (GEO) was used as the primary resource for microarray expression data in 
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this study. GEO is a Minimum Information About a Microarray Experiment (MIAME)-
compliant public repository for researcher-deposited microarray, next generation 
sequencing and other forms of high throughput functional genomics data [106]. It 
stores data in well-organized hierarchies – Platform, Sample and Series records - 
that allow for easy accessibility. These are all submitter-provided records. Platform 
records contain summary descriptions of the array or sequencer. A data table that 
defines the array template is also included for array-based platforms. A platform 
record, although assigned a unique and stable GEO accession number (GPLxxx), is 
not specific to a single submitter and may refer to many samples submitted by 
multiple researchers on that specific platform. Sample records describe the biological 
samples, the handling and protocols it underwent and the abundance measurement 
of each element derived from it. A sample record is also assigned a unique GEO 
accession number (GSMxxx). In this case, however, the number is unique to the 
specific sample entity. Series records provide a description and focal point for the 
whole study as it links related samples together. Series records are assigned unique 
and stable GEO accession numbers (GSExxx). There is a higher level of 
organisation of GEO data – DataSet records. These are GEO series records that 
have been manually curated and reassembled by the GEO staff. A DataSet thus 
represents a collection of biologically and statistically comparable GEO samples 
[106]. They are also assigned GEO accession numbers (GDSxxx) and serve as the 
basis of GEO’s suite of tools for data display and analysis. 
 
The GWAS catalogue and GEO were queried for studies matching the following 
T2D-related terms:  “fasting glucose-related traits”, “fasting insulin-related traits”, 
“fasting plasma glucose”, “insulin resistance/response”, “insulin traits”, “diabetes-
related insulin traits”, “pro insulin levels” “Type 2 diabetes”, “type 2 diabetes and 6 
quantitative traits” and “type 2 diabetes and other traits”. These are descriptive terms 
directly taken from the GWAS catalogue and applied to GEO. 
 GWAS Data  
 Study Selection and Retrieval  
The GWAS catalogue was downloaded as a tab-delimited text file from the NHGRI 
website [103, 104] and queried offline for studies matching the 10 descriptive terms 
according to the aforementioned criteria. The text file was accessed with Microsoft’s 
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Excel program and sorted with the in-built “sort” function.  The “disease/trait” column 
was used as the primary sorting column for studies that matched the set criteria. 
These studies, together with their accompanying curated information, were selected 
and copied to a blank spread sheet. This spread sheet was adopted as the main 
document for the publicly retrieved GWAS data for this study.  
 Gene Expression Studies Data 
 Genes and SNPs Lists Generation 
The genes from the “reported” genes column in the main document were selected to 
provide what is referred to as the “GWAS Genes list”. The “GWAS SNPs list” 
resulted from the “SNPs” column from the same spread sheet. For clarity in the 
downstream analyses, the lists will be referred to accordingly.  
 
 Study Selection 
GEO was queried directly online for T2D-related terms as previously indicated.  This 
search was, however, limited to human data and studies done on the Affymetrix 
platform to reduce any possible bias that may result from the combination of studies 
done on different platforms. The choice of the Affymetrix platform stemmed from the 
comparably larger number of studies appearing in the search results that had been 
carried out on the platform at the time of this selection. 
 Data Retrieval and Analyses 
Each study was individually retrieved from GEO series records via GSE accession 
numbers and analysed using a number of Bioconductor packages in R. R is a 
computational language and an open source environment with a suite of software 
facilities for data manipulation, calculation and graphical display [107]. The basic 
functionality of R is easily extended by the availability of packages that cover a wide 
range of modern statistics and bioinformatics via its Bioconductor platform. 
Bioconductor is bioinformatics-centred and provides tools for high-throughput data 
analyses [108]. Bioconductor packages were frequently utilized for the analyses 
done in this study. For the expression data retrieval and analyses, the GEOquery 
[109], affy [110] and limma [111] packages were used.  
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First, the raw intensity data (.cel files) from each study together with their associated 
phenotypes (case (T2D), control, or other conditions), as specified by the originating 
study author, were retrieved and organized using the getGEO and getGEOSuppFiles 
functions in the GEOquery package. The GEOquery package serves as a bridge 
between the GEO repository and Bioconductor. It allows for data to be easily 
retrieved with very minimal to no manipulation.  The retrieved raw data were read 
with the ReadAffy function, in the affy package, into an AffyBatch object. An 
AffyBatch object is an R class representation for probe level Affymetrix GeneChip 
data comprising mainly of multiple array intensities. This is an important data 
formatting step for some of the downstream analysis. The affy package contains a 
suite of tools for exploratory analysis of oligonucleotide arrays. Applying the rma 
function to the AffyBatch object, also contained in the affy package, pre-processed 
the data using the Robust Multichip Average (RMA) method [112]. This is a three-
step method that involves background correction, quantile normalization [113] and 
summarization. These corrected data are then organized in a matrix of gene 
expression measures with the exprs function creating an expression set object 
(exprSet). Expression values, phenotypic and other related information are usually 
stored in exprSet objects. This was then used for differential gene expression 
analyses with the limma package. 
 
The Linear Models for Microarray Data, limma, package is a Bioconductor 
implementation of the use of linear models to assess differential expression in 
microarray data. The general aim is to make an otherwise complex analysis 
relatively straightforward provided that the right parameters are designated. The 
limma approach was applied to this study by first specifying a ‘design matrix’ which 
indicates which RNA target has been hybridized to each array. This was done using 
the model.matrix function. This function identifies and organizes the different 
conditions present in the data set. A linear model is then fitted for each gene on the 
array, based on the design matrix, using the lmFit function, in order to systematically 
model the experimental data so that it can be differentiated from random variation. 
To make comparisons between conditions (as defined in the design matrix), a 
‘contrast matrix’ (cont.matrix) was specified. Using the makeContrasts function, the 
contrast matrix was designed to directly compare T2D cases against controls, 
regardless of any other condition that may have been considered in the original 
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study. The contrasts.fit function allows for the fitted coefficients of the contrast matrix 
to be compared in several different ways. The eBayes function employs an empirical 
Bayes method on the fitted contrasts’ coefficients to assess differential expression of 
probes and compute a number of statistics. Some of the resulting statistics from 
limma analysis include adjusted p-values for multiple testing, unadjusted p-values, 
log fold changes as well as F-, B- and t-statistics, which all contribute to the 
identification of probes that represent genes that have been differentially expressed 
in an experiment. The t-statistic in limma is a linear one that is easily applied to 
microarray data. It was developed from the hierarchical model of Lönnstedt and 
Speed [114, 115] and is based on a model where variances of the residuals vary 
from gene to gene and are assumed to be drawn from a scaled chi-square 
distribution [111] unlike the standard t-statistic where the assumption is that both 
groups are sampled from normal distributions with equal variances [116]. The 
moderated F-statistic in limma is an overall test of significance that combines the t-
statistics of all the contrasts. It tests to see if any of the contrasts are non-zero for 
each gene, that is, if a gene is differentially expressed on any contrast. The B-
statistic (B or lods) is the log-odds that a gene is differentially expressed [111]. 
 
The limma statistic utilized for gene selection in this study was the Benjamini-
Hochberg (BH) adjusted p-value. This is a p-value that has been adjusted for 
multiple testing with the BH method to control the false discovery rate [117]. This 
simply means that, if a threshold of 0.05 is chosen, all the genes below this threshold 
are considered to be differentially expressed and the expected proportion of false 
discoveries in the set is controlled to be 5% of the set of genes. The use of adjusted 
p-values is important because p-values, as with other model-based methods, 
depend on mathematical assumptions and normality, which are not usually precisely 
true for microarray data [111]. 
 
The R script used for the gene expression studies analysis can be found in electronic 
(EA1). 
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 Gene List Generation 
The differential expression analysis resulted in the identification of Affymetrix probes 
that needed to be annotated for clarity. The getSYMBOL function in the annotate 
package [118], together with the corresponding downloaded Affymetrix genome 
array annotation data, were  used to match the differentially expressed Affymetrix 
probes to gene symbols. This provided a data frame for probes and their 
corresponding official gene symbols together with their limma statistics. A BH-
adjusted p-value ≤ 0.05 was chosen as the cut-off for genes to be considered as 
being significantly differentially expressed in each of the selected studies. To create 
a core list of genes from these Affymetrix-based expression studies, the genes 
meeting the adjusted p-value criteria were only considered for further analysis if they 
were found to be significant in more than one of the selected studies based on tissue 
or array similarities. For example, comparisons were made between studies with 
samples originating from skeletal muscle tissue and not between studies with 
samples from the skeletal muscle and blood tissues. Likewise, studies done on the 
GeneChip Human Genome U133 array, for example, were directly compared with 
each other thereby allowing for relatively “like” comparisons. The resulting 
intersecting genes provided what is referred to as the “Expression Genes list”. 
 
2.1.2 SNP Data (1000 Genomes) 
The 1000 Genomes data was mined to allow for the analysis of both the GWAS 
SNPs (risk allele frequency) and the SNPs associated with the genes that result from 
the functional analysis section in a population context. 
To get some understanding of the genes via their corresponding markers in a 
population context, the 1000 Genomes project [119] data were interrogated. The 
1000 Genomes project is a human genome reference project that aims to discover 
most of the genetic variants with frequencies of at least 1% in the studied 
populations by the low coverage (4X-6X) sequencing of many individuals. This 
includes individuals from different populations in the Americas, Asia, Africa and 
Europe. The populations of interest in this study from those present in the 1000 
Genomes project are: LWK (Luhya in Webuye, Kenya), YRI (Yoruba in Ibadan, 
Nigeria), CEU (Utah Residents with Northern and Western European ancestry), TSI 
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(Toscani in Italia), CHB (Han Chinese in Beijing, China) and JPT (Japanese in 
Tokyo, Japan) (Table 2.1). 
 
PLINK [120] was used in the retrieval of the relevant 1000 Genomes data from the 
cream-ce server in the high performance cluster at the University of the 
Witwatersrand, which housed files that were already converted from their native .vcf 
format to PLINK-ready files. PLINK is an open source whole genome association 
analysis toolset that efficiently computes a range of basic, large-scale analyses. It is 
particularly useful for its convenient handling and manipulation of large data sets like 
whole genome data which contains several thousands of markers genotyped for 
thousands of individuals. PLINK consists of five main functional domains: population 
stratification, identity-by-descent estimation, data management, association analysis 
and summary statistics. For the purposes of this research, the data management 
domain served the major needs of the analyses of the 1000 Genomes data set. 
 
Table 2.1 1000 Genomes population interrogated in this study. AFR = Africa, ASN = 
Asia, and EUR = Europe. 
 
Population Description Population 
Code 
Super 
Population 
Code 
Sample 
size 
Luhya in Webuye, Kenya LWK AFR 97 
Yoruba in Ibadan, Nigeria YRI AFR 88 
Han Chinese in Beijing, China CHB ASN 97 
Japanese in Tokyo, Japan JPT ASN 89 
Utah Residents with Northern and Western 
European ancestry 
CEU EUR 85 
Toscani in Italia TSI EUR 98 
 
2.2 Functional Analysis 
To get some biologically meaningful insight into different gene combinations of the 
genes present in the both the Expression Genes list and the GWAS Genes list, they 
were interrogated with the Database for Annotation, Visualization and Integrated 
Discovery (DAVID) [121]. 
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2.2.1 Overview of DAVID 
 
DAVID is a bioinformatics resource kit that provides a comprehensive set of 
functional annotation tools which can be useful in the understanding of biological 
meanings of large gene lists derived from genomic studies [122]. This kit consists of 
a knowledgebase as well as other integrated, web-based functional annotation and 
analytical tool suites. These include text and pathway-mining tools such as gene 
name batch viewer, functional annotation chart, functional annotation clustering, and 
gene functional classification tool amongst others. The DAVID knowledgebase is a 
gene-centred database [121]. It is very comprehensive as it integrates a huge array 
of the major and well-known public bioinformatics resources centralized by the 
DAVID gene concept, a single-linkage method to amass millions of gene/protein 
identifiers from several public genomic resources into DAVID gene clusters [121]. 
This allows for an improved cross-reference capability where more than 40 publicly 
accessible functional annotation sources can be comprehensively integrated and 
centralized by DAVID gene clusters. 
 
The gene functional classification tool contributes towards a systematic 
enhancement of the biological interpretation of large gene lists as it groups genes 
based on their functional similarities. It generates a gene to gene similarity matrix 
from over 75,000 terms (including pathways like the KEGG, REACTOME, 
PANTHER, and BIOCARTA pathways) and 14 functional annotation sources [122] 
with the clustering algorithms classifying highly related genes into functionally related 
groups. The functional annotation tool primarily provides batch annotation and gene-
Gene Ontology (gene-GO) term enrichment analysis thus highlighting the most 
relevant GO terms associated with a gene list.  
 
The vast annotation content coverage - over 40 annotation categories, including GO 
terms, protein-protein interactions, protein functional domains, disease associations, 
bio-pathways, sequence general features, homologies, gene functional summaries, 
gene tissue expressions and literatures - as well as the flexible options to display 
results makes it a very powerful tool within this kit for investigators to analyse genes 
from different biological aspects in a single space. The results display options 
include the functional annotation chart report which provides an annotation term-
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focused view of the genes being investigated. In this report, a one-tail Fisher’s Exact 
statistic, denoted as an EASE score, is calculated and the results shown to be 
statistically significant have to had passed the default DAVID thresholds. Other 
optional statistics available in this chart view are Fold Enrichment values as well as 
Benjamini, Bonferroni and FDR corrected p-values. This tool was greatly utilized in 
this study for gene set enrichment and reduction purposes. 
 
The GWAS Genes list and the Expression Genes list were separately analysed by 
DAVID with the same parameters for prioritised gene selection. 
2.2.2 Criteria for Prioritized Gene Selection 
The categories and options selected in DAVID for core gene selection are listed in 
Table 2.2. 
 
Table 2.2 Options selected in DAVID for analysis. 
DAVID Categories Selected Options 
Disease  OMIM Disease, Genetic Association DB-Disease 
Gene_Ontology GO_TERM BP_FAT 
Pathways BBID, BIOCARTA, KEGG, PANTHER 
 
The Online Mendelian Inheritance in Man, OMIM, Disease database [123] is a freely 
available and daily updated collection of human genes and genetic phenotypes that 
contains over 12,000 genes and information on all identified Mendelian disorders. 
The Genetic Association DB-Disease is a collection of human genetic association 
studies of complex diseases and disorders, including data extracted from published 
papers on GWAS and candidate gene studies [124].  These options were selected in 
the disease category of the DAVID tool because of the vastness of the databases in 
their collection of genes and associated phenotypes for both monogenic and 
complex traits.  
 
Gene ontology (GO) is a powerful method of interpreting and summarizing biological 
functions from a given list of genes [125]. However, redundant terms do occur in the 
enriched GO list that usually has little, if any, additional information to the analysis. 
The GO Fat database was developed as part of the Annotation Tool in DAVID to 
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combat the challenge of redundancies in the enriched GO lists. The Gene Ontology 
Biological Process, GO_TERM BP_FAT, [121, 122] is thus a subset of the 
classification of gene products in the hierarchy of the computationally amenable 
encyclopaedia of gene functions and their relationships, comprising more specific 
terms. The Biological Biochemical Image Database, BBID, [126] is a searchable 
database of images of possible biological pathways, gene families, macromolecular 
structures, and cellular relationships. BIOCARTA [127] is a biological pathways 
resource that provides representations of gene-to-gene interactions in an easy-to-
read diagram. It is a constantly evolving resource as it is constantly updated by new 
research from the scientific community. The Kyoto Encyclopaedia of Genes and 
Genomes, KEGG, [128] is a database resource that allows for the understanding of 
high-level functions and importance of the biological system, from molecular-level 
information. This is especially beneficial for large-scale molecular datasets 
generated by high-throughput experimental technologies like genome sequencing. 
The Protein ANalysis THrough Evolutionary Relationships (PANTHER) database 
[129, 130] is a system of proteins and their genes that have been classified 
evolutionarily by related proteins, biological processes and pathways. These 
selected options for the Gene_Ontology and Pathways categories in DAVID allow for 
possible functional relatedness of genes as well as various levels of gene-gene 
interactions to be explored. 
 
These databases were interrogated by DAVID in the search for functionality and 
enrichment of the genes contained in the two genes lists with the Functional 
Annotation Chart report thresholds left as DAVID’s defaults: count = 2 (minimum 
number of genes in the input list for the corresponding term) and EASE = 0.1 
(maximum P-value/EASE score).  
 
A Bonferroni-adjusted p-value ≤ 0.05 in DAVID’s functional annotation chart was set 
as the threshold for significance of annotation results. The Bonferroni correction 
method adjusts the data for false positives or type I errors that can result from 
multiple testing [131]. This method, although quite conservative, was chosen in this 
case because of its easy and wide application to different kinds of data sets.  The 
genes associated with the terms and pathways that met this criterion for both the 
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Expression and GWAS Genes lists were combined to provide a core list of genes for 
downstream analysis that is simply referred to as the “Gene list”. 
2.3 Population (Allele) Frequency Analysis 
To get some understanding of the genes via their corresponding markers in a 
population context, the 1000 Genomes project [119] data were interrogated via 
PLINK.  
2.3.1 T2D Risk Allele Frequency Distribution 
The GWAS SNPs list was directly analysed to assess the distribution of identified 
T2D risk allele frequencies across the six 1000 Genomes populations of interest. 
This was done by identifying the presence or absence of a risk allele from the GWAS 
SNPs list in each individual in these populations. The frequency of occurrence of 
each allele in these populations was calculated based on the number of risk alleles 
in each individuals belonging to the different populations. A frequency chart was then 
plotted to visualise and compare the risk alleles’ distribution in the African, European 
and Asian populations. This was done using an in-house custom Perl script (EA 2) 
(personal communication, Dr. Ananyo Choudhury). 
 
2.3.2 SNPs List Generation 
An already converted PLINK-ready (binary files) recent version of the .vcf files of the 
1000 Genomes data (Phase1, version 3, October 2012) was accessed on the local 
cream-ce server at Wits University. This version containing about 36.7 million 
autosomal SNPs and 1.38 million short structural variants (SSVs) [132] was the 1000 
Genomes data source for this study.   
 
The coordinates of the genes resulting from the enrichment analysis by DAVID were 
retrieved using the Ensembl Biomart [133]. Using these coordinates, a text file 
containing the ranges of each gene, that is, the start and end chromosomal position 
together with the corresponding chromosome number, a ‘range’ file was created. 
This file was used in PLINK to retrieve SNPs associated with the genes from the 
1000 Genomes data. In retrieving the SNPs, the ‘--geno’ and ‘--mind’ commands 
were used to control for missingness in the data.  
plink --bfile 1000-all --geno 0.025 --mind 0.025 --extract Ensembl_Genes_Ed.txt --range --recode 
--out V_Rec_Final_1000-all 
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The ‘--geno’ and ‘--mind’ thresholds were both set to 0.025. This means that 
individuals with more than 2.5% of missing genotype data will be excluded and only 
SNPs with a greater than 97.5% genotyping rate will be included in the resulting 
output file. This subset of the 1000 Genomes data served as the primary 1000 
Genomes data of relevance in this study and was subsequently analysed for 
population-specific variances. A random set of SNPs of almost similar size was also 
retrieved from the 1000 Genomes data using the ‘--thin’ command in PLINK.  
plink --bfile 1000-all --geno 0.025 --mind 0.025 --thin 0.0040 --make-bed --out 
RandomSample1k 
 
The ‘--thin’ command is a flag that allows for the retrieval of a specified percentage 
of SNPs from the input data based on random sampling. This random set of SNPs 
was retrieved to serve as control for the specifically selected gene-associated 
primary data used in this study and is simply referred to as the Random SNPs list. 
2.3.3 Highly Relevant SNPs Selection 
In order to identify population-specific variants, pairwise fixation indices (FST) and 
integrated Haplotype Scores (iHS) were calculated for the different populations.  
 
 FST Calculations 
FST is the basic statistical measurement of differentiation between populations 
originally proposed by Sewall Wright [134]. It is generally a measure of the reduction 
in heterozygosity in populations. It is also seen as the proportion of genetic diversity 
resulting from allele frequency differences among populations [135]. FST provides 
important insights into the evolutionary processes that influence the structure of 
genetic variation within and among populations and is a commonly used descriptive 
statistic in population and evolutionary genetics [135]. FST estimates can be used in 
the identification of regions of the genome that have been selection targets. This 
statistic was calculated using an in-house Perl script that closely mirrors Wright’s 
[134] implementation of the estimator. This script was validated against the snpStats 
R package’s implementation of FST [136]. 
 
Attribute text files of pairwise combinations of interest were created using the ‘grep’ 
function at the command line to retrieve the specified pairwise combinations from an 
existing master attribute file on the local cream-ce server at Wits University. This 
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master attribute file accompanied the download of the original .vcf 1000 Genomes 
data. These files generally contain the individuals’ identification and the populations 
to which they belong. Pairwise FST calculations were done for each of the African 
populations versus the populations from Europe and Asia. The resulting file was 
cleaned by removing the ‘NAs’ and negative values.  FST values generally range from 
0 to 1, where a zero implies that the populations being considered are freely 
interbreeding, that is complete panmixis [134]. A value of one indicates that the 
populations being considered do no share any genetic diversity and as a result any 
genetic variation observed can be attributed to the population structure.  An FST cut-
off for “very great” genetic differentiation was set at 0.25, mirroring Wright’s 
suggested degree of divergence thresholds shown in table 2.3 [137]. This cut-off was 
applied to the primary dataset as well as to the randomly selected SNPs. 
 
Table 2.3 Wright’s suggestions for interpreting genetic differentiation. 
FST values Wright’s Guidelines 
0 – 0.05 Little differentiation 
0.05 – 0.15 Moderate differentiation 
0.15 – 0.25 Great differentiation 
> 0.25 Very great differentiation 
 
The SNPs were to be annotated to their corresponding genes to allow for the 
combined analysis of these SNPs from a gene perspective. This was done in R 
using the merge function. The merge function is part of the base package in R and 
allows for the joining of two data frames by a row or column common to both data 
sets. To accomplish this, the previously retrieved set file was reformatted to contain 
two columns – gene and SNP to allow for a relatively straightforward merging 
process. This file was loaded into R and merged with the FST pairwise result via the 
SNP column common to both files. The SNP count per gene was done for both the 
significant set and the total set of SNPs using the summary function in R. 
 
For the SNPs meeting the 0.25 threshold, stochastic simulation of p-values as well 
as overrepresentation scores were computed. To calculate these values, the ratio of 
the number of significant SNPs per gene to the total number of SNPs in each gene 
was calculated. This gave the ‘observed’ value. The ratio of the number of significant 
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SNPs in the random gene set to the total number of retrieved random SNPs present 
in the populations compared was also calculated, giving the ‘expected’ ratio. Only 
SNPs with rsIDs were used in these calculations. The p-value was calculated as a 
hypergeometric distribution of these 4 values – significant SNPs per gene, total 
number of SNPs in each gene, significant SNPs in random gene set and total 
number of retrieved random SNPs present in population comparison - in Microsoft’s 
Excel 2010. The HYPGEOMDIST function in Excel was used to perform this 
analysis.  It calculates the probability of a given number of successes from a sample 
of a population given the 4 aforementioned parameters. The successes in this case 
refer to the number of SNPs that meet the initial cut-off of an FST value of 0.25.  The 
overrepresentation score was calculated as the ratio of the observed value to the 
expected value for each gene.   A gene was thus considered significantly diverged, 
in this study, if it had an FST value ≥ 0.25, a p-value ≤ 0.05 and an overrepresentation 
score of at least 2. This was done for each pairwise combination. This empirically 
defined cut-off was employed to allow for the selection of potentially robust FST 
values to control for possible errors that might be introduced as a consequence of 
the polymorphism of the dataset.   
 
A combination of the pairwise SNP results by continents prior to the stochastic p-
value and overrepresentation score calculation was done to produce one merged file 
per continent. The significantly diverged SNPs based on an FST ≥ 0.25 in the 
CEU_LWK, CEU_YRI, TSI_LWK and TSI_YRI pairwise analyses were combined 
into a non-redundant set to give the African versus European (AFR_EUR) 
comparison. Similarly, the combination of significant SNPs in the CHB_LWK, 
CHB_YRI, JPT_LWK and JPT_YRI pairwise analyses produced the African versus 
Asian (AFR_ASN) comparison. P-values and overrepresentation scores were then 
computed with these combined files. The intersecting SNPs from the AFR_EUR and 
AFR_ASN sets, also prior to overrepresentation scores and p-value calculations, 
make up the African versus non-African (AFR_nonAFR) SNPs list that was 
subsequently annotated to their corresponding genes using the merge function as 
explained above, to give the AFR_nonAFR gene list. Similar p-value and 
overrepresentation score calculations (as previously described) were done on this 
list to give the final FST AFR-nonAFR gene list. 
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 Integrated Haplotype Score (iHS) Calculations 
The main purpose of these calculations was to identify possible signatures of 
selection in the African population. The iHS is a statistic that detects evidence of 
recent positive selection at a locus based on the differential levels of linkage 
disequilibrium surrounding a positively selected allele compared to the background 
allele at the same position [138]. It is an extended haplotype homozygosity (EHH)-
based analysis approach that is widely used for detecting recent and strong natural 
selection. The basic idea driving such an analysis is that a haplotype with high 
frequency and high homozygosity that extends over a considerably long stretch of 
genome often corresponds to regions under an incomplete selective sweep.  One of 
the landmark examples of such a selection was detected in the lactase region (LCT), 
where selection on lactase-persistence into adulthood is a trait that has been subject 
to a selective sweep in European (and some African populations) which has not 
completely fixed [139]. This method relies on the linkage-disequilibrium structure of 
local regions of the genome for identifying tracts of homozygosity within a 'core' 
haplotype, using the EHH as a statistic. The EHH is summed over all sites away 
from a core SNP, and compared between the haplotypes that carry the ancestral and 
the derived alleles in the SNP. The iHS therefore gives a numerical indication of the 
amount of extended haplotype homozygosity along the ancestral allele at a given 
SNP with respect to the derived allele. This statistic is normalized to have a mean of 
0 and variance of 1 and standardized empirically to the distribution of observed 
scores over a range of SNPs with similar derived allele frequencies to make them 
comparable to each other [138]. 
A ‘set’ file was created in PLINK from the list of gene-associated SNPs generated 
from the 1000 Genomes data. A set file in this instance sorts, organizes and lists the 
SNPs according to their associated genes. This action, referred to as sub-setting in 
PLINK, was accomplished using the ’--write-set’ flag together with the previously 
described text file of ranges containing chromosome number and base positions of 
genes.  
plink --file V_Rec_Final_1000-all --make-set Ensembl_Genes_Ed.txt --write-set --out 
V_Rec_Final_Set_1000-all 
The ‘iHS_calc’ script from the WHAMM package [140] was used to carry out the iHS 
calculations for each of the 6 populations. WHAMM is an open source analysis 
package that, amongst other functions, estimates patterns of homozygosity in whole 
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genome data sets like the 1000 Genomes [141] and HapMap [142–144]. For iHS 
calculations to be done using this script, the physical positions of the SNPs needed 
to be specified. This information can either be obtained from the LD architecture of a 
dataset (like the 1000 Genomes data) using tools like LDHat [145] or incorporated 
from existing physical maps which have been identified using thousands of 
individuals from different populations.  
 
As the aim of this study was to identify the relative strength of signatures of selection 
in certain genomic regions compared to others rather than identifying novel 
signatures, physical position-based maps were chosen over LD-based maps. The 
Rutgers’ combined linkage physical map for human genome (build GrCh37) was 
thus downloaded [146] and used to incorporate the required physical positions into 
the 1000 Genomes data. The Rutgers combined linkage physical map is a high-
resolution genetic map that comprises the largest set of polymorphic markers with 
publicly-available genotype data. This map is well-suited as a comprehensive 
resource for determining genetic map information as the position of most of the 
included markers are corroborated by both recombination-based data and genetic 
sequence [146].  It incorporates SNPs as well as sequence-based positional 
information. However, an already incorporated file from [141] was utilized. EHH was 
thus integrated with respect to genetic distance in cM. The background distribution 
for each population was estimated by randomly sampling of 10,000 50-SNP blocks 
and calculating the iHS for the SNPs occurring in these blocks. The iHS scores were 
subsequently standardized based on the allele frequency bins derived from the 
background. The ancestral allele assignment was done according to the ancestral 
state information provided by the 1000 Genomes Consortium, which was based on a 
4-way EPO alignment of human, chimpanzee, orangutan and rhesus macaque [119]. 
An initial cut-off for significance of SNPs was set at an absolute iHS value of 2.  
iHS analysis was done on a random sample of 100,000 SNPs for each of the 
populations to calculate an expected ratio to serve as control for the study data iHS 
results.  
 
As was done with the FST values, a stochastic simulation of p-values as well as 
overrepresentation scores based on observed versus expected ratios were 
computed for each gene. A gene was considered selected if it had a p ≤ 0.05 and an 
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overrepresentation score of at least 2. Since selection is being investigated primarily 
in the African populations, emphasis is placed on the LWK and YRI populations.  
 
2.3.4 Africa-identified vs. Non-Africa-identified SNPs and Genes List 
The criteria for SNPs and their corresponding genes to be considered significant in 
this study, with the overarching aim of identifying African-specific variants associated 
with T2D risk and/or pathogenesis, was for the SNP to show differentiation (based 
on set study thresholds in the FST analysis) between African and non-African 
populations and selected by virtue of its presence in the iHS final gene list in the 
African populations. 
 
A PhenoGram plot [147] was used to present a graphical summary of the resulting 
SNP numbers with different colours representing the SNPs meeting the different cut-
offs and thresholds of significance at various stages of the analyses.  
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3 CHAPTER THREE – RESULTS 
This study is divided into 3 sections – public data mining, functional analyses of the 
mined data and population frequency analyses to put the study in a population-
specific context. 
3.1 Public Data Mining 
3.1.1 T2D-associated Studies 
 GWAS Data 
The GWAS catalogue was initially accessed on 1 June, 2012 and updated on 2 
September, 2013. At this point, there were a total of 51 T2D-associated studies 
(Table 3.1) matching the set search criteria. The matching studies were published 
from the year 2007 to 2013. 218 SNPs were reported to be very strongly associated, 
at p < 10-5, with type II diabetes according to these 51 studies. This makes up the 
GWAS SNPs list. The genes linked to these SNPs, as reported by the original 
studies, are 175. These genes make up what will be referred to as the GWAS Genes 
list. The difference between the number of SNPs and genes can be accounted for by 
the presence of multiple SNPs from the same gene being identified as strongly T2D-
associated in different studies which would reduce the gene list, as well as SNPs 
occurring in intergenic regions. The participants in the selected studies’ data sets 
comprised a wide range of ethnicities. These include individuals of European 
descent, Hispanic ancestry, African-Americans, Indian-Asians, Mexican-Americans, 
Japanese, Chinese, Malaysians, Filipinos and Koreans. The studies were mainly 
carried out on Affymetrix and Illumina platforms with sample sizes ranging from 187 
to meta analyses including over 46,000 individuals. 
 
Table 3.1 51 GWA Studies meeting the set search criteria 
Date Study 
2013 Genome-wide association study in a Chinese population identifies a susceptibility 
locus for type 2 diabetes at 7q32 near PAX4 [148]. 
2013 Genome-wide association study identifies a novel locus contributing to type 2 
diabetes susceptibility in Sikhs of Punjabi origin from India [149]. 
2012 A single-nucleotide polymorphism in ANK1 is associated with susceptibility to type 2 
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diabetes in Japanese populations [150]. 
2012 A genome-wide approach accounting for body mass index identifies genetic variants 
influencing fasting glycemic traits and insulin resistance [61]. 
2012 1000 Genomes-based imputation identifies novel and refined associations for the 
Wellcome Trust Case Control Consortium phase 1 Data [151]. 
2012 A genome-wide association study identifies GRK5 and RASGRP1 as type 2 diabetes 
loci in Chinese Hans [152]. 
2012 Stratifying type 2 diabetes cases by BMI identifies genetic risk variants in LAMA1 and 
enrichment for risk variants in lean compared to obese cases [153]. 
2012 Fasting glucose GWAS candidate region analysis across ethnic groups in the Multi-
ethnic Study of Atherosclerosis (MESA). [154] 
2012 Genome-wide association study identifies novel loci association with fasting insulin 
and insulin resistance in African Americans [155]. 
2012 A genome-wide association search for type 2 diabetes genes in African Americans 
[156]. 
2012 Genome-wide association study for type 2 diabetes in Indians identifies a new 
susceptibility locus at 2q21[157]. 
2011 Genome-wide association identifies nine common variants associated with fasting 
proinsulin levels and provides new insights into the pathophysiology of type 2 
diabetes [158]. 
2011 Genome-wide detection of allele specific copy number variation associated with 
insulin resistance in African Americans from the HyperGEN study [159]. 
2011 Genome-wide association study in individuals of South Asian ancestry identifies six 
new type 2 diabetes susceptibility loci [160]. 
2011 Transferability of type 2 diabetes implicated loci in multi-ethnic cohorts from 
Southeast Asia [161]. 
2011 Genome-wide association study of type 2 diabetes in a sample from Mexico City and 
a meta-analysis of a Mexican-American sample from Starr County, Texas [162]. 
2011 A genome-wide association study confirms previously reported loci for type 2 
diabetes in Han Chinese [163]. 
2011 Meta-analysis of genome-wide association studies identifies eight new loci for type 2 
diabetes in east Asians [164]. 
2011 Genome-wide association and meta-analysis in populations from Starr County, 
Texas, and Mexico City identify type 2 diabetes susceptibility loci and enrichment for 
expression quantitative trait loci in top signals [165]. 
2011 Use of diverse electronic medical record systems to identify genetic risk for type 2 
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diabetes within a genome-wide association study [166]. 
2010 Twelve type 2 diabetes susceptibility loci identified through large-scale association 
analysis [167]. 
2010 A genome-wide association study in the Japanese population identifies susceptibility 
loci for type 2 diabetes at UBE2E2 and C2CD4A-C2CD4B [168]. 
2010 Identification of new genetic risk variants for type 2 diabetes [169]. 
2010 New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 
diabetes risk [170]. 
2010 Genetic variants at 2q24 are associated with susceptibility to type 2 diabetes [171]. 
2010 A genome-wide association study identifies susceptibility variants for type 2 diabetes 
in Han Chinese [172]. 
2009 Confirmation of multiple risk Loci and genetic impacts by a genome-wide association 
study of type 2 diabetes in the Japanese population [173]. 
2009 Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and 
hyperinsulinemia [174]. 
2009 Common genetic variation near melatonin receptor MTNR1B contributes to raised 
plasma glucose and increased risk of type 2 diabetes among Indian Asians and 
European Caucasians [175]. 
2009 A genome-wide association scan for acute insulin response to glucose in Hispanic-
Americans: the Insulin Resistance Atherosclerosis Family Study (IRAS FS) [176]. 
2009 Candidate loci for insulin sensitivity and disposition index from a genome-wide 
association analysis of Hispanic participants in the Insulin Resistance Atherosclerosis 
(IRAS) Family Study [177]. 
2008 SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian 
and European populations [98]. 
2008 Adiposity-related heterogeneity in patterns of type 2 diabetes susceptibility observed 
in genome-wide association data [178]. 
2008 A polymorphism within the G6PC2 gene is associated with fasting plasma glucose 
levels [179]. 
2008 Variations in the G6PC2/ABCB11 genomic region are associated with fasting glucose 
levels [180]. 
2008 Meta-analysis of genome-wide association data and large-scale replication identifies 
additional susceptibility loci for type 2 diabetes [181]. 
2008 Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus [99]. 
2008 Variants in MTNR1B influence fasting glucose levels [182]. 
2008 A variant near MTNR1B is associated with increased fasting plasma glucose levels 
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and type 2 diabetes risk [183]. 
2007 A variant in CDKAL1 influences insulin response and risk of type 2 diabetes [68]. 
2007 Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride 
levels [184]. 
2007 Genome-wide association study of 14,000 cases of seven common diseases and 
3,000 shared controls [185]. 
2007 A genome-wide association study identifies novel risk loci for type 2 diabetes [186]. 
2007 A genome-wide association study of type 2 diabetes in Finns detects multiple 
susceptibility variants [60]. 
2007 Genome-wide association with diabetes-related traits in the Framingham Heart Study 
[187]. 
2007 Replication of genome-wide association signals in UK samples reveals risk loci for 
type 2 diabetes.[188] 
2007 Identification of type 2 diabetes genes in Mexican Americans through genome-wide 
association studies [189]. 
2007 A search for variants associated with young-onset type 2 diabetes in American 
Indians in a 100K genotyping array [190]. 
2007 Identification of novel candidate genes for type 2 diabetes from a genome-wide 
association scan in the Old Order Amish: evidence for replication from diabetes-
related quantitative traits and from independent populations [191]. 
2007 A 100K genome-wide association scan for diabetes and related traits in the 
Framingham Heart Study: replication and integration with other genome-wide 
datasets [192]. 
2007 Type 2 diabetes whole-genome association study in four populations: the DiaGen 
consortium [193]. 
 
To summarise, the genes from the “reported” genes column in the main GWAS 
catalog document were selected to provide what is referred to as the “GWAS Genes 
list” and the “GWAS SNPs list” resulted from the “SNPs” column of the same spread 
sheet. For clarity in the downstream analyses, these lists will be referred to 
accordingly. These genes and SNPs can be found in Appendix I. 
 
 Gene Expression Studies Data 
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 Data Retrieval and Analyses 
The NCBI’s GEO repository was accessed in May, 2012. The number of studies 
meeting the stringent search criteria, on Affymetrix platforms, at this point was 10. 
The studies were published from the years 2003 – 2011 and comprised 5 studies 
with samples from the skeletal muscle, 2 from the liver, 1 from blood tissue and 2 
from the pancreatic tissue. The sample donors included Asian, European, European-
American, Mexican American and African-American individuals. These studies were 
carried out on Affymetrix platforms Hu6800, Hu133A, Hu133B, Hu95A, Hu95Av2, 
Hu133_X3P and Hu133Plus2. The relatively large number of studies with skeletal 
muscles probably stems from the notion that insulin resistance in the skeletal muscle 
is the earliest detectable abnormality in individuals with a high risk for T2D [194] and 
the fact that it is an easier tissue to access than the liver or pancreas. The 
microarray expression studies are listed in Table 3.2. 
 
Table 3.2 Gene expression studies meeting the set search criteria. 
Study # GSE # Study Title Year Tissue 
1 21340 Coordinated reduction of genes of oxidative 
metabolism in humans with insulin resistance and 
diabetes: Potential role of PGC1 and NRF1 [194]. 
2003 Skeletal Muscle 
2 9006 Gene expression in peripheral blood mononuclear 
cells from children with diabetes [195]. 
2007 Blood 
3 22309 The effect of insulin on expression of genes and 
biochemical pathways in human skeletal muscle 
[196]. 
2007 Skeletal Muscle 
(Vastus Lateralis) 
4 12643 Transcriptional profiling of myotubes from patients 
with T2D: no evidence for a primary defect in 
oxidative phosphorylation genes [197]. 
2008 Skeletal Muscle 
(Myotubes) 
5 15653 Thyroid hormone-related regulation of gene 
expression in human fatty liver [198]. 
2009 Liver 
6 20966 Gene expression profiles of Beta-cell enriched 
tissue obtained by laser capture micro dissection 
from subjects with T2D [199]. 
2010 Pancreatic 
Tissue (b-cells) 
7 18732 Integration of microRNA changes in vivo identifies 
novel molecular features of muscle insulin 
2010 Skeletal Muscle 
(Vastus Lateralis) 
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Study 1, carried out on the Affymetrix HG-U6800 platform, investigated gene 
expression in skeletal muscle from metabolically characterized non-diabetic 
individuals, regardless of family history of T2D, and type 2 diabetic Mexican- 
American individuals. The study showed that the reduced expression of a number of 
nuclear respiratory factor-1 (NRF-1)-dependent genes that encode some of the key 
enzymes in mitochondrial function and oxidative metabolism play noticeable roles in 
T2D and insulin resistance. Although the down-regulation of NRF-1 was only 
observed in the diabetic cases, the expression of PPAR gamma co-activator 1-alpha 
and-beta (PGC1-alpha/PPARGC1 and PGC1-beta/PERC), co-activators of NRF-1 
and PPAR gamma-dependent transcription, was decreased in both diabetic 
individuals and non-diabetic controls with a family history of T2D [194]. These genes, 
however, did not meet the significance threshold set for differential expression 
consideration for this study.  
There were 20 raw intensity (.cel) files available for the limma analysis for study 1. 
The contrast matrix created compared diabetic samples to control samples with no 
family history. This required the analysis of only 11 of the available 20 files – T2D (5) 
and control (6). A similar comparison in the original study resulted in 187 genes 
being identified as differentially expressed with no gene showing significant 
differential expression at an unspecified BH-adjusted p-value threshold. However, 47 
genes met the BH-adjusted p ≤ 0.05 initial significance threshold for this study. Some 
of the high ranking genes based on the adjusted p-values are ATP synthase, H+ 
transporting, mitochondrial F1 complex, beta polypeptide, ATP5B, oxoglutarate 
(alpha-ketoglutarate) dehydrogenase (lipoamide), OGDH and heat shock 70kDa 
protein 1A  HSPA1A. 
resistance in T2D [200]. 
8 23343 A liver-derived secretory protein, selenoprotein P, 
causes insulin resistance [201]. 
2010 Liver (Hepatic 
Tissue) 
9 25724 Class II phosphoinositide 3-kinase regulates 
exocytosis of insulin granules in pancreatic beta 
cells [202]. 
2011 Pancreatic 
Tissue (Islets) 
  10    25462 Increased SRF transcriptional activity in human 
and mouse skeletal muscle is a signature of insulin 
resistance [203]. 
  2011  Skeletal Muscle 
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Study 2 was carried out on two platforms. For the purposes of this work, Study 2A 
will refer to the analysis done on the HG-U133A platform and Study 2B will refer to 
the analysis done on the HG-U133B platform. The original study aimed to show that 
the changes in gene expression in peripheral blood mononuclear cells as a result of 
counter-regulatory responses to immune dysregulation, insulin deficiency, 
hyperglycemia as well as the dysregulation of adaptive and innate immunity, 
accompany type I diabetes (T1D). However, samples were retrieved from individuals 
with T2D, and pathways and genes common to both T1D and T2D were also 
investigated hence the availability of T2D samples. 
 
There were 234 raw intensity (.cel) files available for limma analysis for study 2, with 
117 raw intensity files used per platform.  The original study included samples from 
type 1 diabetic individuals at two time points after diagnosis and at diagnosis, type 2 
diabetic individuals at diagnosis and non-diabetic individuals as controls. The 
contrast matrix created for this study compared the samples from type 2 diabetic 
individuals directly to those of the control group. No T1D samples were analysed. 35 
of each set of 117 files were, therefore, used for analysis – T2D (11) and control 
(24). As the main purpose of the original study was not primarily related to this 
comparison, its result was not explicitly stated in the paper. However, 18 of the 22 
most highly differentially expressed genes in T1D were noted to be similarly 
differentially expressed inT2D at a False Discovery Rate (FDR) of 0.01 [195]. At the 
set threshold for initial significance in this study, 1,083 and 377 genes were found to 
be differentially expressed in study 2A and 2B respectively. Some of these genes are 
insulin-degrading enzyme, IDE, insulin-like growth factor binding protein 3, IGFBP3, 
and potassium inwardly-rectifying channel, subfamily J, member 1, KCNJ1. 
 
Study 3, carried out on the Affymetrix HG-U95A platform, aimed to study the effects 
of insulin on gene expression in the skeletal muscle and provide insight into the 
underlying defects causing insulin resistance and the molecular basis of insulin 
action in skeletal muscle [196]. 
 
One hundred and ten (110) raw intensity (.cel) files were used for the limma analysis 
of this study. The original study probed both treated and untreated insulin-resistant 
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and insulin-sensitive samples as well as treated and untreated diabetic samples. The 
contrast matrix created for this study compared the two extremes – untreated 
diabetic samples and untreated insulin-sensitive samples. As a result, 35 of the 110 
files were used for analysis – T2D (15) and control (20). 4,410 genes from this 
comparison met the initial differential expression significance cut-off. Some of these 
genes are insulin-like growth factor 1 receptor, IGFR1, nuclear receptor subfamily 4, 
group A, member 1, NR4A1, and serum response factor, SRF. 
 
Study 4 aimed to investigate the possible co-existence of reduced mitochondrial 
biogenesis with impaired insulin responsiveness in the early stages of the 
pathogenesis of T2D as it has been shown to co-exist with insulin resistance in both 
high-risk and type 2 diabetic individuals. This study, done on the Affymetrix  HG-
U95Av2 platform, was accomplished by comparing samples from the myotubes 
(skeletal muscle) of obese diabetic individuals with matched obese healthy patients . 
No gene was found to be significantly differentially expressed in the original study 
after correction for multiple testing was done using thresholds of either a false 
discovery rate (FDR) < 0.01 or a family-wise error rate (FWER) < 0.05.  
 
Twenty (20) raw intensity (.cel) files were available for the limma analysis of study 4. 
The original study involved a direct comparison between samples from diabetic 
individuals and a control group. The contrast matrix created for this study compared 
likewise. The result of the limma analysis done for the samples in this study 
correspond to the original study analysis as no genes were found to be differentially 
expressed at a BH-adjusted p ≤ 0.05.  
 
Study 5 aimed to identify novel transcriptional changes in the human liver that could 
possibly contribute to hepatic lipid accumulation, the associated insulin resistance 
and its complication, T2D, as well as non-alcoholic steatohepatitis [198]. In the 
original study, liver biopsies were taken from obese individuals, with and without T2D 
as well as from lean non-diabetic individuals. This study was done on the Affymetrix 
HG-U133A platform. For the purposes of this work, only the samples from the obese 
diabetic individuals were assigned to the case group while samples from the lean 
study participants were regarded as control in the contrast matrix. One of the 
analyses done in the original study involved a direct case-control comparison as 
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such and 91 genes were found to be differentially expressed at Q < 0.001 using an 
unspecified Bioconductor package [198]. Q values generally measure the proportion 
of false positives when a test is considered significant [204]. The specific method of 
this correction implemented to give this Q value, was, however, unclear. The idea 
was to compare two extremes as specified in the contrast matrix. But this may not 
have been the best comparison for this study as obesity is confounding factor in T2D 
and obese controls might have been better suited.  
 
Fourteen (14) of the available 18 raw intensity (.cel) files available for the limma 
analysis for this study – T2D (9) and control (5) - were analysed. Using the set 
threshold of BH-adjusted p < 0.05, 31 genes were found to be significantly 
differentially expressed. Some of these genes include small nuclear 
ribonucleoprotein polypeptide E, SNRPE, catenin (cadherin-associated protein), 
delta 1, CTNND1 and ATPase, Ca++ transporting, type 2C, member 1, ATP2C1. 
 
Study 6, carried out on the Affymetrix HG-U133_X3P platform, aimed to gain some 
insight into the abnormal secretion of insulin that occurs in the pathogenesis of T2D 
by investigating changes in gene expression in pancreatic b-cells [199]. This was 
done by the laser capture dissection of frozen sections of pancreases of diabetic and 
non-diabetic human cadavers. This method of dissection was applied to overcome 
the possible limitations that may have resulted from the use of isolated islet 
preparations that may affect gene expression changes and the presence of non-beta 
cells, duct cells and acinar cells in the islets [205].  
 
The 20 available raw intensity (.cel) files available for the limma analysis for this 
study were used – T2D (10) and control (10).  At an unadjusted p < 0.01, the original 
study found 1,870 genes to be differentially expressed. This was not entirely 
replicated in this current work as only 750 genes were found to be differentially 
expressed at that p-value. At the set threshold of BH-adjusted p < 0.05, however, 
only 2 genes were significant - neurofilament, light polypeptide, NEFL, and MyoD 
family inhibitor domain containing, MDFIC.  
 
Study 7 aimed to elucidate the mode of action and importance of microRNAs 
(miRNAs) in complex human diseases.   In addition to the primary miRNA analyses, 
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microarray expression analysis was done on muscle biopsies from the vastus 
lateralis (skeletal muscle) of samples from individuals with impaired glucose 
tolerance (IGT), normal glucose tolerance (NGT) (control) and T2D [200]. This study 
utilized the Affymetrix HG-U133Plus2 platform. 
Ninety-one (91) of the available 120 raw intensity (.cel) files were used for the limma 
analysis in this study – T2D (45) and control (46). The contrast matrix for this study 
directly compared the T2D samples to the control. A similar comparison in the 
original study with both the Significance Analysis of Microarrays, SAM [206] and 
limma yielded no differentially expressed genes. The significance cut-off used was 
not specified probably because of the focus on miRNA analysis. At a BH-adjusted p 
≤ 0.05 in this study, however, 3 genes were found to be differentially expressed. 
These genes are SET domain, bifurcated 2, SETDB2, HECT domain containing E3 
ubiquitin protein ligase 1, HECTD1, and nucleoporin like 1, NUPL1.  
Study 8, carried out on Affymetrix HG-U133Plus2 platform, aimed to identify hepatic 
secretory proteins involved in insulin resistance and specifically focused on the role 
of selenoprotein P, SeP, in the control of glucose metabolism and insulin sensitivity 
[201]. 
Seventeen (17) raw intensity (.cel) files were used for the limma analysis in this 
study - T2D (10) and control (7). The original study probed samples from individuals 
with T2D and normal glucose tolerance, regarded as the control group. The contrast 
matrix in this study was thus created accordingly.  At the set BH-adjusted p ≤ 0.05, 
cut-off for initial significance, no gene was differentially expressed. 
The primary aim of study 9 was to demonstrate the role of class II phosphoinositide 
3-kinase (PI3K-C2α) in the secretion of insulin in pancreatic b-cells. The original 
study also probed the possible alterations in the levels of PI3K-C2α in T2D, hence 
the availability of T2D samples [202]. The Affymetrix HG-U133A platform was utilized 
for this analysis.  
Thirteen (13) raw intensity (.cel) files were the input for limma analysis - T2D (6) and 
control (7). The original study compared samples from type 2 diabetic individuals to 
samples from non-diabetic individuals. The contrast matrix for this study was created 
accordingly – T2D vs Control. This comparison yielded 4,355 genes being 
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differentially expressed at the initial cut-off for significance. Some of these genes are 
transcription factor 7-like 2 (T-cell specific, HMG-box), TCF7L2, HNF1 homeobox B, 
HNF1B, and hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA 
hydratase (tri-functional protein), alpha subunit, HADHA. 
Study 10, carried out on the Affymetrix HG-U133Plus2 platform, aimed to identify 
transcriptional phenotypes associated with T2D by analysing the expression of 
genes in the quadriceps (skeletal muscle) in samples from individuals with T2D,  
non-T2D individuals with a parental history of T2D  and samples from non-T2D 
individuals without any T2D history - the control group [203]. The study specifically 
demonstrated the role of serum response factor, SRF, activity in insulin resistance. 
 
Twenty-five (25) of the 50 available raw intensity (.cel) files were used for the limma 
analysis in this study - T2D (10) and control (15). The contrast matrix created for this 
study, like in the previous instances, directly compared the T2D samples to the 
control. 4 genes were differentially expressed at a BH-adjusted p ≤ 0.05. These 
genes are actin-binding Rho activating protein, ABRA, cysteine-rich, angiogenic 
inducer, 61, CYR61, nuclear receptor subfamily 4, group A, member 1, NR4A1, and 
kyphoscoliosis peptidase, KY. The number of differentially expressed genes was not 
stated in the original study paper, ABRA was noted as a top-ranking that has been 
previously identified as an activator of SRF transcriptional activity [203, 207].  
 Genes List 
Using a BH-adjusted p < 0.05 as the cut-off for significantly differentially expressed 
genes, 2 of these studies were eliminated giving a total of 7,887 genes from 8 
studies (EA 4). This cut-off, although stringent, produced widely varying gene 
numbers from each study. As a result, an additional criterion was applied to the 
current list of differentially expressed genes to further increase the confidence in the 
list of genes used for downstream analyses. This requirement for genes to be 
significantly differentially expressed in more than one study, based on platform or 
tissue type, resulted in 497 genes. This list of genes is referred to as the Expression 
Genes List (Appendix II).  
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3.2 Functional Analysis 
The GWAS genes list comprising 175 genes was uploaded to DAVID. 162 of these 
genes mapped to DAVID’s IDs. This means that only 162 of the 175 genes 
corresponded to DAVID’s internal annotation that facilitates a comprehensive 
navigation of gene-associated annotation across several databases. A Bonferroni-
adjusted p ≤ 0.05 was set as the threshold for significance in this enrichment step. 
16 terms/pathways met this cut-off in DAVID’s functional annotation chart and 
resulted in a list of 46 genes – genes overlap across the different categories. These 
terms and pathways can be seen in Table 3.3. Running these genes through 
DAVID’s functional annotation clusters resulted in several levels of enrichment. 
Figure 3.1 shows a chart of gene ontology (GOTERM_BP_FAT) terms of these 46 
genes with the top 3 enrichment scores clusters. 
Table 3.3 Significantly enriched terms and pathways from the GWAS genes list. 
Category Term Gene   
Count 
Bonferroni 
OMIM_DISEASE Meta-analysis of genome-wide 
association data and large-scale 
replication identifies additional 
susceptibility loci for type 2 
diabetes 
21 2.45 x 10-34 
GENETIC_ASSOCIATION_DB_DISEASE diabetes, type 2 28 3.23 x 10-12 
OMIM_DISEASE Replication of genome-wide 
association signals in UK samples 
reveals risk loci for type 2 
diabetes 
9 4.70 x 10-12 
OMIM_DISEASE Genome-wide association 
analysis identifies loci for type 2 
diabetes and triglyceride levels 
9 4.70 x 10-12 
OMIM_DISEASE A genome-wide association study 
of type 2 diabetes in Finns detects 
multiple susceptibility variants 
9 4.70 x 10-12 
KEGG_PATHWAY hsa04950:Maturity onset diabetes 
of the young 
9 1.59 x 10-08 
GENETIC_ASSOCIATION_DB_DISEASE diabetes, type 2 triglycerides 6 1.01 x 10-05 
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GENETIC_ASSOCIATION_DB_DISEASE diabetes, gestational 8 2.41 x 10-05 
GOTERM_BP_FAT GO:0042593~glucose 
homeostasis 
9 2.51 x 10-05 
GOTERM_BP_FAT GO:0033500~carbohydrate 
homeostasis 
9 2.51 x 10-05 
OMIM_DISEASE Adiposity-related heterogeneity in 
patterns of type 2 diabetes 
susceptibility observed in genome 
wide association data 
5 4.98 x 10-05 
GOTERM_BP_FAT GO:0031016~pancreas 
development 
7 0.0012569 
KEGG_PATHWAY hsa04930:Type II diabetes 
mellitus 
6 0.0167522 
GOTERM_BP_FAT GO:0007346~regulation of mitotic 
cell cycle 
10 0.020368 
GOTERM_BP_FAT GO:0009743~response to 
carbohydrate stimulus 
7 0.0315192 
GENETIC_ASSOCIATION_DB_DISEASE insulin 7 0.0327099 
 
The 497 genes of the expression genes list were uploaded to DAVID. 485 of these 
genes mapped to DAVID’s IDs. 9 terms/pathways met the set Bonferroni-adjusted p 
≤ 0.05 cut-off, resulting in 96 genes. These terms and pathways can be seen in 
Table 3.4. Again, the genes overlapped across the terms so that a summation of the 
gene count column would not result in 96 because of redundancies. Running these 
genes through DAVID’s functional annotation clusters resulted in different levels of 
enrichment. Figure 3.2 shows a chart of the functional annotation clusters (gene 
ontology terms) of these 96 genes with the top 2 enrichment scores clusters. 
Table 3.4 Significantly enriched terms and pathways from the expression genes list. 
Category Term Gene 
Count 
Bonferroni 
GOTERM_BP_FAT GO:0006396~RNA processing 52 2.17 x 10-09 
GOTERM_BP_FAT GO:0006397~mRNA processing 38 7.76 x 10-09 
GOTERM_BP_FAT GO:0008380~RNA splicing 35 2.14 x 10-08 
GOTERM_BP_FAT GO:0016071~mRNA metabolic process 39 1.30 x 10-07 
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GOTERM_BP_FAT GO:0000398~nuclear mRNA splicing, via 
spliceosome 
22 2.02 x 10-05 
GOTERM_BP_FAT GO:0000377~RNA splicing, via trans 
esterification reactions with bulged adenosine as 
nucleophile 
22 2.02 x 10-05 
GOTERM_BP_FAT GO:0000375~RNA splicing, via trans 
esterification reactions 
22 2.02 x 10-05 
KEGG_PATHWAY hsa03040:Spliceosome 18 2.13 x 10-04 
GOTERM_BP_FAT GO:0010605~negative regulation of 
macromolecule metabolic process 
46 0.015568 
 
About 4 percent of the combined total number of genes (663 non-redundant genes) 
was excluded from the annotation process and subsequent analyses as a result of 
the absence of DAVID IDs. However, the combination of the resulting genes from 
this enrichment analysis with DAVID produced a non-redundant list of 140 genes 
with an overlap of 2 genes between the GWAS and expression results. The list of 
140 genes is henceforth referred to as the Gene List which is the core gene set for 
downstream analysis in this study. This list can be found in Appendix III. 
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Figure 3.1 Functional annotation terms based on genes from the top 3 GWAS genes 
enriched clusters in DAVID. 
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Figure 3.2 Functional annotation terms based on genes from the top 2 microarray 
expression genes enriched clusters in DAVID. 
 
3.3 Population (Allele) Frequency Analysis 
3.3.1 Risk Allele Frequency Analysis 
Of the 218 SNPs identified in the GWAS studies, the risk alleles for 58 of them were 
not indicated. It is common practice to assign the risk allele as the minor allele in the 
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population being studied. Even though this is very often an accurate assumption, it is 
not always the case. I therefore decided to err on the side of caution and only include 
the SNPs where the risk allele was clearly stated and excluded those with missing 
risk alleles in the GWAS catalog. The risk allele frequency analysis was thus carried 
out with 160 SNPs. 157 of these SNPs were identified by the 1000 Genomes data 
meaning that the maximum number of risk alleles possible per individual ranged from 
0 to 314 (157 SNPs X 2 alleles) as an individual could have either 0, 1  or 2 risk 
alleles at each SNP locus. This produced the resulting frequency distribution plot in 
Figure 3.3. The allele distribution observed here corroborates previously reported 
findings on 12 T2D risk alleles in a similar intercontinental frequency plot that the risk 
alleles for T2D are clearly present in higher frequencies in sub-Saharan Africa than 
in Asia and Europe [208]. A T-test was done to substantiate the observed risk allele 
differences where the null hypothesis was rejected for the Asian/African and 
European/African comparisons but not for the Asian/European comparison. This is 
shown in table 3.5. 
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Figure 3.3 GWAS SNPs list risk allele frequency distribution. A shows the 
distribution of all 157 SNPs and B zooms in on the region (inset in A) of obvious 
intercontinental differences.  
Table 3.5 Risk allele frequency distribution T-test results. Comparisons with p-values 
less than 0.0001 are in bold fonts. 
Pairwise 
Comps 1 
Avg. No. of 
Risk Allele 
Occurrence 
Risk 
Alleles 
Used 
Pairwise 
Comps 2 
Avg. No. of 
Risk Allele 
Occurrence 
T-
Score 
P-value Null 
Hypothesis 
CEU#TSI 140.22 157 LWK#YRI 153.28 13.56  <10-12 Rejected 
CHB#JPT 140.13 157 LWK#YRI 153.28 13.27  1.62 x 10-11 Rejected 
CEU#TSI 140.22 157 CHB#JPT 140.13 0.08  0.93832 Not 
rejected 
 
3.3.2 SNP List Generation 
The Ensembl database (release 73) was interrogated via its biomart package 
implementation, ‘biomaRt’ [209] in R for the retrieval of the co-ordinates of the genes 
contained in the gene list. The attributes retrieved, of the 140 genes resulting from 
the GWAS analysis and expression array studies following analysis in DAVID, 
include the chromosome name, start and end positions of the genes on the 
chromosome as well as the strand information. The result was saved as a tab-
delimited text file which was subsequently converted to a space-delimited text file 
that was a preferred input data format for PLINK. The retrieved file showed 3 of the 
140 genes to be located on sex chromosomes – 2 (NONO and RBM3) on the X 
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chromosome and 1 on the Y chromosome (RBMY1A1) which were excluded from 
further analyses. 
 
The attributes needed to retrieve the SNPs associated with the genes list are the 
chromosome name and the gene’s start and end position on the chromosome. The 
space delimited text file was thus adjusted accordingly to create a file with these 
positional ranges. This file was used to query the 1000 Genomes data on the local 
cream-ce server at Wits University. The missingness threshold of 0.025 that was set 
reduced the incorporation of incomplete genotype data in the resulting SNPs list.  
 
The query produced a list of 154,144 autosomal SNPs that were used in 
downstream analysis. These SNPs served as the main 1000 Genomes data set for 
this study. Knowing the total number of SNPs contained in the entire 1000 Genomes 
data made it possible for an estimate to be made of the percentage of this total that 
would give a relatively comparable, albeit not the exact number, of random SNPs to 
serve as control for the selected gene list SNPs. A random set of SNPs was included 
in this study to serves as a control data set and eliminate any bias that might be 
introduced into the results by intra-data analysis. Hence, the results from the random 
sample combinations were utilized in the p-value calculations that were critical to the 
assessment of SNP/gene significance in this study. 
 
The ‘--thin’ command was set to randomly retrieve 0.40% of the total SNP count of 
the 1000 Genomes. This flag was used together with the same missingness 
parameters in the main data set. This resulted in a list of 151,713 random SNPs that 
is subsequently referred to as the Random SNPs list. 
 SNP List Analysis 
To facilitate the population analysis aspect of this study, a number of files needed to 
be created. A ‘set’ file containing the SNPs in each gene, ordered by base position, 
was created using the same file with chromosome position ranges previously used in 
the retrieval of SNPs corresponding to the 137 genes. This was accomplished with 
the ‘--make-set’ and ‘--write-set’ commands in PLINK. An ‘attribute’ text file, 
containing the identification for each individual together with the population group to 
which they belong, for each pairwise population combination, [MyTSI_YRI] for 
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example, was created from an existing master attribute file on the cream-ce server at 
Wits University. The attribute files were used to create population pairwise versions 
of the 1000 Genomes data that were used for downstream analysis. Table 2.1 shows 
the numbers of individuals present in each of the 1000 Genomes populations 
interrogated in this study. 
 FST  
The in-house Perl script utilized the population group data from the attribute files and 
the genotype information from the corresponding 1000 Genomes data to calculate 
pairwise FSTs. Table 3.5 shows a summary of the FST results from the pairwise 
combinations – CEU_LWK, CEU_YRI, TSI_LWK, TSI_YRI, CHB_LWK, CHB_YRI, 
JPT_LWK and JPT_YRI – of the SNPs that meet the initial cut-off of 0.25 for 
significant genetic differentiation. A similar pattern of differentiation was also 
observed with the random SNPs list (Table 3.6 bottom table). 
 
 
 
Table 3.6 Pairwise FST analysis results. The top table shows the results from the 
study data and the bottom table shows the random set results 
 
Study 
Data 
CEU_LWK CEU_YRI TSI_LWK TSI_YRI CHB_LWK CHB_YRI JPT_LWK JPT_YRI 
Total 
SNPs 
154144 154144 154144 154144 154144 154144 154144 154144 
FST≥0.25 
SNPs 
Genes 
 
1179 
77 
 
1541 
83 
 
1102 
73 
 
1367 
76 
 
2194 
83 
 
2524 
83 
 
2201 
90 
 
2581 
91 
Random 
Set 
CEU_LWK CEU_YRI TSI_LWK TSI_YRI CHB_LWK CHB_YRI JPT_LWK JPT_YRI 
Total 
SNPs 
151713 151713 151713 151713 151713 151713 151713 151713 
FST≥0.25 
SNPs 
 
1291 
 
1577 
 
1158 
 
1444 
 
1916 
 
2172 
 
1961 
 
2228 
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Only SNPs with rsIDs were considered in SNP counts in subsequent analysis. The 
number of genes meeting the stochastic p ≤ 0.05 and an overrepresentation score of 
at least 2, for each pairwise comparison are in brackets: CEU_LWK (13), CEU_YRI 
(9), TSI_LWK (10), TSI_YRI (6), CHB_LWK (7) and JPT_LWK (5). A combination of 
the African/European and the African/Asian pairwise SNP results produced the 
AFR_EUR (39) and AFR_ASN (45) comparisons respectively. 824 SNPs 
representing 63 genes were common to both intercontinental SNPs lists at the initial 
FST ≥ 0.25 cut-off, giving the AFR_nonAFR SNPs list for that threshold. The final FST 
results for the AFR_nonAFR comparison, however, indicate that 7 genes from 228 
SNPs are significantly differentiated between Africans and non-Africans. 2 (Notch 
homolog 2, NOTCH2, Kinesin Family member 11, KIF11) of these genes originate 
from the GWAS analysis, 4 (Nuclear Receptor Subfamily 2, NR2F2, Ribosomal 
Protein L35A, RPL35A, Small Nuclear Ribonucleoprotein D1 Polypeptide 16kDa, 
SNRPD1, and RNA Guanylyltransferase And 5'-Phosphatase, RNGTT) from the 
gene expression analysis and 1 (RNA binding motif protein 38, RBM38) from both.  
 
Figure 3.4 shows genes with SNPs that met the FST ≥ 0.25 cut-off. A list of the 
AFR_nonAFR comparison genes and their corresponding SNPs can be found in 
Appendix IV.   
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Figure 3.4 Intercontinental FST comparisons. The blue bars indicate the ratio of SNPs that met the set cut-off to the total number of 
SNPs present per gene. 
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Figure 3.5 Combined intercontinental FST comparisons. The blue bars indicate the 
ratio of SNPs that met the set cut-off to the total number of SNPs present per gene. 
 
 Integrated Haplotype Score (iHS) Analysis 
The main purpose of the iHS analysis in this study is to identify possible signatures 
of selection in the African population. The results from the custom iHS_calc script 
from the WHAMM package usually comprise positive and negative scores. Absolute 
values of iHS were used as the designation of positive or negative scores is usually 
determined by the lengths of haplotypes on the ancestral and derived allele 
backgrounds relative to each other. A positive score means that the haplotypes on 
the ancestral allele background are longer compared to the derived allele while a 
negative score implies that the reverse is the case. Under this model, selected 
derived alleles are expected to contain excessive LD relative to the background. 
However, positive iHS scores greater than 2 are also considered as candidates for 
selection. This is because the ancestral allele may be hitchhiking along with the 
selected allele, or is itself a target for selection.  Therefore selection could be in 
either direction. It is important to note that other measures for detecting signatures of 
selection could have been utilized. However, the choice of iHS for this study 
stemmed from the need to identify strong selection signals. Furthermore it is a 
frequently used tool in population genetic studies and is therefore regarded as a 
reliable instrument. 
 
Of the 100,000 SNPs used in the random iHS run, the number of SNPs with |iHS| > 
2 for each of the populations is indicated in brackets – CHB (5,594), JPT (5,112), TSI 
(6,164), CEU (6,164), LWK (6,140) and YRI (5,928).   
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The initial iHS result from the YRI population comprised 59,774 SNPs representing 
137 genes. 1,895 SNPs representing 106 genes met the |iHS| > 2 cut-off. Of these 
genes, 2 appeared to be selected based on the calculated p-value and 
overrepresentation score thresholds. These genes are GRSF1 and SNRPD1. for the 
LWK population contained 59,774 SNPs representing 137 genes. The initial iHS 
result from the YRI population comprised 55,899 SNPs representing 133 genes. 
1,681 SNPs (107 genes) met the |iHS| > 2 cut-off with only 2 of these genes meeting 
the set p-value and overrepresentation score thresholds. The genes are SNRPD1 
and ADAM30.  A summary of the iHS results for the six study populations can be 
seen in Table 3.7. 
 
Table 3.7 iHS analysis results for the six study populations. 
 LWK YRI CEU TSI CHB JPT 
All SNPs  
(Genes) 
59,774 
(133) 
55,899 
(133) 
36,282  
(134) 
55,899  
(133) 
34,173  
(131) 
34,690  
(133) 
SNPs with |iHS| > 
2 (Genes) 
1,895 
(106) 
1,681 
(107) 
892  
(83) 
1,812  
(107) 
2005 
(111) 
878  
(85) 
Selected Genes 
(p < 0.05 
Overrepresentation 
score > 2) 
2 
(GRSF1, 
SNRPD1) 
2 
(ADAM30, 
SNRPD1) 
1 
(SFPQ) 
1 
(SNRPD1) 
8 (IRS1, 
NCOR1, 
BOP1, 
TCERG1, 
FOXA2, 
RPL11, 
CRYM, 
PDCD4) 
3 (BOP1, 
FOXA2, 
FADS1) 
 
 
This analysis shows one T2D gene, SNRPD1, which was significantly differentiated 
from the non-African populations based on FST results to be selected in African 
populations even though it was also selected in one of the European populations, 
TSI. The SNPs contained in the LWK SNRPD1 (15), however, are not exactly the 
same as those found in the YRI and TSI populations (18 SNPs). Nine SNRPD1 
SNPs overlap across these three populations, two (rs2959527 and rs34202260) of 
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which was also had high FST values. Six SNPs in this gene appear to be unique to 
the LWK population, 1 of which appears to be highly differentiated in AFR_non-AFR 
comparisons and is in high LD with three other selected LWK SNRPD1 SNPs. 
Table 3.8 shows a list of the iHS-selected SNRPD1 SNPs in the YRI and LWK 
populations. The nine SNRPD1 SNPs that appear to show significant population 
differentiation between Africans and non-Africans are rs2847117, rs2847139, 
rs2850556, rs2850558, rs2850568, rs2959525, rs2959527, rs3017641 and 
rs34202260. 
The PhenoGram plot [147] in figure 3.6 below shows the distribution of the 824 
SNPs representing 64 genes that showed significant genetic differentiation between 
the African and non-African populations based on the initial FST ≥ 0.25 threshold. The 
colour codes indicate the SNPs that met the cut-offs of subsequent calculations. For 
example, red shows the SNPs that not only have FST values greater than 0.25 but 
also have a stochastic p < 0.05 and an overrepresentation score above 2. 
Table 3.8 SNRPD1 SNPs. The top and bottom tables show the list of SNPs selected 
in the YRI and LWK populations respectively. SNRPD1 is located on chromosome 
18. POS = Base Position, DAF = Derived Allele Frequency and std_iHS = 
Standardized Integrated Haplotype Score. 
 
SNP POS DAF std_iHS 
rs138550124 19194968 0.0114 2.256 
rs138737742 19195302 0.0114 2.171 
rs142407732 19205213 0.0227 2.037 
rs142827866 19199483 0.1023 2.082 
rs182398649 19205277 0.108 2.96 
rs186258230 19200019 0.017 2.229 
rs187422483 19195514 0.0284 2.272 
rs192860228 19202139 0.0511 2.494 
rs193270098 19205527 0.0114 -3.618 
rs2850560 19198301 0.1875 2.723 
rs28675778 19201316 0.1193 2.759 
rs2959527 19204607 0.1023 2.971 
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rs3017643 19205141 0.1818 2.003 
rs73960450 19203507 0.1193 2.345 
rs74546622 19197425 0.1136 2.122 
rs78726174 19198070 0.1136 2.071 
rs9947856 19195083 0.1193 2.143 
 
 
SNP POS DAF std_iHS 
rs142827866 19199483 0.1392 2.492 
rs149186410 19197804 0.0258 3.762 
rs182398649 19205277 0.1701 2.775 
rs185881584 19204969 0.0103 2.081 
rs2847139 19198959 0.067 2.662 
rs2850560 19198301 0.2165 2.271 
rs28675778 19201316 0.0825 3.066 
rs2959526 19204474 0.1701 2.829 
rs2959527 19204607 0.1082 3.144 
rs3017643 19205141 0.1701 2.812 
rs34202260 19199672 0.1598 3.561 
rs73960450 19203507 0.0825 2.743 
rs9947856 19195083 0.0825 2.06 
rs9950960 19201795 0.0412 2.038 
rs9964889 19201845 0.0412 2.038 
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Figure 3.6 Genomic distribution of 824 SNPs representing 64 genes differentiated 
between African and non-Africans. All 824 SNPs met the FST ≥ 0.25. Blue is the 
default colour of all the SNPs present. Light green circles indicate SNPs that also 
met the p ≤ 0.05 and overrepresentation score > 2 threshold (228 SNPs representing 
7 genes). The red circle shows the SNP that was selected only in the LWK 
population and happens to be in high LD with the 3 SNPs indicated by pink circles. 
The dark blue circle shows the two SNPs that appeared to be selected in the TSI, 
YRI and LWK populations. 
From the different analyses to identify T2D genes of high significance in the African 
populations, SNRPD1 would be the highest ranking because of its proposed 
selection (iHS) and population differentiation (FST) in this study. However, the six 
other highly differentiated genes (NOTCH2, NR2F2, RBM38, RPL35A, SART1, and 
RNGTT) very likely also give some insight into the pathogenesis of T2D in Africa. An 
updated research workflow showing the resulting gene numbers at each step is 
shown below. 
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Figure 3.7 Research workflow with corresponding analyses of outcomes.  
GWAS SNPs List (218) 
1000 Genomes 
data 
Identify SNPs associated with genes  
(154,144)  
 
List of highly relevant SNPs and their 
associated genes with possible association to 
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Meta-analyses 
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Expression 
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Public data mining 
GWAS Studies 
(51) 
Expression 
Studies (10) 
Functional Analysis/Selection 
of Genes (DAVID) 
Functional Analysis/Selection 
of Genes (DAVID) 
Terms and Pathways 
(Bonferroni-adjusted P ≤ 0.05) 
(96 genes) 
T2D Risk Allele 
Population 
Frequencies 
Terms and Pathways 
(Bonferroni-adjusted P ≤ 0.05) 
(46 genes ) 
Non-redundant Core Genes List (140) 
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4 CHAPTER FOUR – DISCUSSION AND CONCLUSION 
4.1  Discussion 
The focus of this study is to gain insight into the pathogenesis of T2D from an African 
perspective by analysing existing non-African data in the context of African genetic 
diversity using the 1000 Genomes database. 
4.1.1 Public Data Mining, Retrieval and Analyses 
The retrieval of studies from the NHGRI’s GWAS Catalog and NCBI’s Gene 
Expression Omnibus were mainly to broaden the scope of the analysis to include 
previous efforts from both GWAS and non-GWAS sources. There are more T2D-
related GWAS in databases than there are of T2D-related microarray expression 
studies as the search results in this study indicated – 51 GWAS compared to 10 
microarray studies. This perhaps highlights the recent research trend in the genetics 
of complex diseases [2]. The total number of genes retrieved from both methods, 
however, is not comparable to the study numbers. This can, perhaps, be attributed to 
the compilation method used by the curators of the GWAS catalog. As stated in the 
methods section, the SNP information extracted from studies that are added to the 
catalog are those of SNPs with the strongest trait association [103]. This means that 
only a few SNPs and their corresponding genes from the entire body of SNPs in a 
study are included in the GWAS catalog, with one gene usually being associated 
with more than one SNP. This very likely limited the number of genes included in this 
analysis and the GWAS catalog report was used without further interrogation of the 
individual studies. The studies from the expression studies database, GEO, required 
further analyses and had no pre-set limitations on significance cut-off values. One of 
the objectives of this study was to create a relatively straightforward analysis pipeline 
that could utilize readily available data in curated databases without manual labour-
intensive individual study data curation. It is also important to note that expression 
studies are gene-focused whereas GWAS are usually SNP-focused. 
157 of the 218 T2D-related SNPs originated from the GWAS produced very 
interesting results in an assessment of risk allele frequencies across the African, 
Asian and European continents. It is possible that the retrieval and inclusion of the 
missing alleles absent from the GWAS catalog might have made the resulting 
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distribution more robust but the purpose of using only robust data would be defeated. 
Besides, the GWAS catalog is a manually curated database and there may have 
been reasons for such exclusions even when the original associated papers 
specified the risk alleles in question. However, purpose of the risk allele frequency 
calculation across the queried populations to assess the distribution of identified T2D 
risk allele frequencies across the six 1000 Genomes populations of interest was 
accomplished. A similar distribution was done in a 2012 PloS Genetics paper with 
only 12 risk alleles [208]. 
The analysis showed that the occurrence of previously identified T2D risk alleles, 
mostly identified in non-African populations, is highest in Africa, with little difference 
seen between Asia and Europe. This is consistent with the phenomenon that 
associates T2D risk alleles with human migration patterns - decrease in frequency as 
migration proceeds from Africa to Europe and Asia [208, 210]. This decrease in 
frequencies could perhaps be attributed to differences in agricultural development 
[211], historical events such as movement out of sub-Saharan Africa to areas with 
different climatic conditions [212] and even the thrifty genotype phenomenon [213]. 
The central premise of the thrifty gene hypothesis is that humans evolved from our 
hunter-gatherer predecessors that had to be efficient in food storage and utilization 
as they had to go through cycles of feast and famine. Natural selection appears to 
have favoured the ancient humans that had bodies that were better adapted to fuel 
storage or utilization as they were more likely to survive the famine portion of the 
cycle [214]. In other words, during famine, a predisposition to insulin resistance may 
have conferred protection or advantage to individuals by favouring glucose use in 
organs that operate through an insulin-independent mechanism like the brain, while 
reducing muscle utilization of glucose [208, 213]. Based on recent T2D prevalence 
statistics, this pattern of risk allele distribution is not exactly intuitive as one would 
expect non-African populations, who have a higher prevalence of T2D than African 
populations, to present higher frequencies of risk alleles since they have existed in a 
more resourced environment for a long period of time. However, environmental 
factors are very important in the aetiology of diabetes and the high prevalence of 
obesity in non-African populations in conjunction with gene-based predisposing 
factors may explain the higher prevalence in the developed world. The increasing 
availability of cheap, highly palatable, calorie-rich food combined with relatively 
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limited physical activity in recent times, appears to have created a situation where 
these previously advantageous thrifty genes now make us vulnerable to metabolic 
diseases like obesity and diabetes [213]. Thus, the incidence of T2D in Africa may 
increase dramatically as this obesogenic environment becomes more prominent 
within African populations harbouring high frequencies of diabetes-associated risk 
alleles.  
This difference in risk allele occurrence and the current T2D incidence rates 
observed between the continents perhaps highlights the influence of the role of 
environmental differences which affect epigenetic risk factors in the occurrence of 
T2D as has been alluded to in previous studies [215].   
The analyses of the expression studies data with limma produced largely varying 
results from no genes being significantly differentially expressed in some studies to 
over 4,000 genes identified in a study as being differentially expressed at a p-value 
corrected to account for multiple testing, a Benjamini-Hochberg p ≤ 0.05. The tissue 
types, sample collection methods, platforms and even study-specific hypotheses 
differences very likely played a role in this widely varying significantly expressed 
gene numbers per study despite using the same basic analysis pipeline. It is 
probably then, not ideal to utilize pipelines for such secondary microarray data 
analysis despite the inclination to do so in this age of automation, as the questions of 
the original study are usually geared towards relatively different aims and objectives.  
For this study it was therefore necessary to generate a core list of genes – 497 
genes – that took both the different tissues and Affymetrix platforms into account. 
Interestingly, only 8 of these genes were also on the GWAS gene list – SRR, AP3B1, 
ARF5, CDC123, FOXN3, GRB10, IDE and RBM38, with only 2 (IDE and RBM38) of 
these genes remaining in the post-DAVID analysis gene list. This represents about 
2% and 4% of the expression and GWAS gene lists respectively, in both the pre- and 
post-DAVID analysis. The small number of overlapping genes between the two 
methods suggests that more genes were incorporated in the analysis as there were 
not many redundant genes. This is probably because GWAS identifies SNPs based 
on the strength of its association to the phenotype of interest whereas gene 
expression studies on the levels of differential expression of genes between cases 
(diabetics) and controls (non-diabetics). It is therefore believed that the combination 
of data from both methods provided a more comprehensive gene set for this study 
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than a single method would have. This combined approach has been previously 
demonstrated in a study that incorporated prostate cancer data sets from microarray 
array analysis and GWAS [216] where there was an overlap of over 80% of the 
genes identified with the two methods. An overlap of this nature would ideally serve 
as a validation of sorts for genes identified from the two experimental methods but 
the number of available study data in T2D have not quite reached the extent of some 
of the more extensively studied diseases like cancer. 
4.1.2 Functional Analysis 
Functionally analysing the GWAS gene lists produced 2 significant KEGG pathways 
– type 2 diabetes and maturity onset diabetes of the young. A GO term that stood 
out from this list was that of GO: 0031016~ pancreas development. Seven (7) of the 
GWAS genes were associated with this term. The pancreas plays a major role in the 
pathogenesis of T2D. The dysregulation of β-cell function in a situation where there 
is an increased insulin demand created by insulin resistance in peripheral tissues 
can attenuate the compensation mechanism to maintain insulin production levels 
and have consequences in the development and pathogenesis of T2D [2, 3]. 
One (1) KEGG pathway – spliceosome – was significant from the analysis of the 
expression gene list. The spliceosome pathway is involved in the assembly of the 
spliceosomal complex that facilitates the trans esterification reactions that lead to 
alternatively spliced mRNA transcripts [217].  
 A closer look at the resulting 46 GWAS and 96 Expression genes contributing to the 
core gene list via functional annotation clusters of the gene ontology terms revealed 
that the highest gene counts were in the regulation of macromolecule and RNA 
biosynthetic and metabolic processes on both lists. This was not entirely unexpected 
as T2D is characterized as a metabolic disorder [1, 18] but it was interesting to see 
that despite the little overlap of genes between the study methods, there was an 
overlap of 24 GO terms with the highest ranking terms on both lists associated with 
metabolic processes. Some of the metabolism-associated GO terms are regulation 
of RNA metabolic process (GO:0051252) from the GWAS analysis and mRNA 
metabolic process (GO:0016071) from the microarray expression analysis. Defective 
RNA metabolism has been previously implicated in the aberrant expression of the 
insulin receptor gene which could have serious consequences for T2D via insulin 
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resistance [218]. These terms created confidence in the data going forward with 
subsequent analyses as the process and method of gene selection was also crucial 
to the study outcome.  
It is, however, important to note that the potential of circular argument does exist in 
the combined use of GWAS/microarray data and functional analysis as databases 
are generally interconnected. As a result, there is a possibility of functions being 
assigned to genes from the GWAS or microarray databases from which the genes 
were identified. Caution thus needs to be taken in the interpretation of the data. Also, 
since gene function is inferred from a gene similarity matrix that involves pathways 
and gene-GO-term enrichment, amongst other measures as previously stated [121, 
122], it is important to take into consideration the dynamic nature of these 
annotations as new information becomes available and that not all of these 
annotations are experimentally validated. Whilst experimentally validated 
annotations are ideal, functional annotations inferred from pathway memberships, 
sequence similarity scores, co-occurrence probability, etc., as utilized to some extent 
by DAVID, tend to provide a relatively good insight into gene functions. A schematic 
overview of some of the significant functional annotation terms associated with 
GWAS and microarray expression studies  and a possible relationship/role in the 
pathogenesis of T2D is shown in figure 4.1 below. 
It is not believed that he exclusion of the 25 genes not identified by DAVID from a 
combined total of 663 non-redundant genes from the analysis in this instance, had a 
substantial impact on the discovery of novel T2D candidates or the research 
outcome as a whole. 
4.1.3 Population (Allele) Frequency Analysis 
The 1000 Genomes project employed a sequence-based approach in its 
identification of many novel SNPs across different populations, and this is one of the 
major achievements of the project [119]. This is in contrast to genotyping-based 
methods used in the Human Genome Diversity Project (HGDP) and HapMap 
projects [142–144, 219, 220]. The 1000 Genomes project provides an unbiased 
estimate of human genetic variation in different populations across the globe [119].  
In analysing the SNPs in a population context, an estimator of genetic differentiation 
was utilized. The fixation index, FST, is amongst the most commonly used estimators 
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of genetic differentiation between populations [221]. The Perl script that was used to 
implement this statistical method allows for the direct input of PLINK data formats, 
thereby minimizing any pre-analysis manipulation of the study data. The number of 
genes that showed inter-continental differentiation after the two-step cut-off criteria 
was considerably small.  However, all but 1 (SNRPD1) have been associated to 
different extents with the pathogenesis of T2D. The NOTCH2 gene encodes a 
member of the Notch family. The resulting protein is cleaved in the trans-Golgi 
network and serves as a receptor for membrane-bound ligands. Notch family 
members tend to influence a variety of developmental processes by controlling cell 
fate decisions - it has been shown to play a role in renal, hepatic and vascular 
development as well as in the implementation of differentiation, proliferation and 
apoptotic programs [222]. NOTCH2 is very likely associated with beta cell function in 
the pancreas as it plays a critical role in the pancreatic development of the fetus 
[223, 224].  
The KIF11 gene encodes a motor family protein. Members of this protein family are 
known to have gene products that are involved in centrosome separation, 
chromosome positioning and establishing a bipolar spindle during mitosis [225].  
KIF11 resides in an established T2D-susceptibility locus on chromosome 10q23.33. 
This locus also houses the insulin-degrading enzyme, IDE and HHEX genes. The 
HHEX-IDE-KIF11 locus was first associated with T2D risk in individuals of European 
ancestry but has also been replicated in Chinese and Japanese populations [64, 
226, 227]. Studies have shown this locus to be associated with increased BMI in 
childhood [228], a risk factor for obesity and T2D, with mRNA and protein levels of 
the KIF11 gene dropping drastically at the start of adipogenesis [229, 230].  
The NR2F2 gene encodes a member of the steroid hormone superfamily of nuclear 
receptors [231]. Also referred to as COUP-TFII, NR2F2 has a broad tissue 
expression profile, including the pancreas. It has been shown to be both a target and 
regulator of the Wnt/beta-catenin signalling system [232, 233], a pathway that is 
involved in insulin sensitivity and adipocyte differentiation [234]. This pathway has 
been shown together with the hedgehog signalling pathway to repress adipogenesis 
in mammalian systems [235]. NR2F2 is known to act downstream of hedgehog 
signalling and is critical to the full expression of the anti-adipogenic effect driven by 
the sonic hedgehog anti-adipogenic factor [236]. It can perhaps then be assumed 
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that a polymorphism in the NR2F2 gene could possibly disrupt its dominant role in 
the repression of adipocyte differentiation [236], which could contribute to the 
development of T2D. 
The RNGTT gene codes for a bi-functional mRNA–capping enzyme that gets 
recruited to the transcription complex by the phosphorylation of RNA polymerase II 
[231]. It is involved with the mRNA surveillance pathway which serves as a quality 
control mechanism that detects and degrades anomalous mRNAs [128]. 
The RPL35A gene encodes a ribosomal protein that is required for the proliferation 
and viability of hematopoietic cells. It is involved in the reactome pathway for the 
metabolism of proteins. This pathway involves the regulation of insulin-like growth 
factor (IGF) transport and the uptake of the insulin-like growth factor binding proteins 
(IGFBPs) some of which are expressed in the liver [237]. Insulin and IGF have 
overlapping functions and control several aspects of growth, survival and metabolism 
in a wide range of mammalian tissues [238]. A dysfunction in the reactome pathway 
could possibly produce disrupted insulin-like effects that might be consequential in 
the development of T2D as insulin and IGF-1 both stimulate the Wnt/beta-catenin 
pathway [239]. 
The RBM38 gene encodes an RNA-binding protein that appears to be expressed in 
a number of tissues including the liver, spleen, lung, brain and pancreas. It is 
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mRNA processing and DNA damage response [231]. This protein binds specifically 
to the 3'-UTR of cyclin-dependent kinase inhibitor 1A, CDKN1A transcripts, thereby 
maintaining the stability of these transcripts [240]. CDKN1A has been shown to have 
altered DNA methylation profile and differential expression in human T2D islets that 
contribute to disrupted insulin and glucagon secretion highlighting the role of 
epigenetics in the pathogenesis of T2D [241]. A SNP near the RBM38 gene has 
been previously identified to be associated with T2D in Punjabis with Pakistani 
ancestry [149]. 
Interestingly, the variants showing great genetic differentiation in this study in genes 
like RBM38, KIF11 and NOTCH2 generally differ from the specific variants that have 
been previously identified to show T2D association in the literature. For example,  
rs328506, rs7923837 and rs1111875, and rs10923931 from RBM38, KIF11 and 
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NOTCH2 respectively were not among the list of highly differentiated SNPs in the 
African populations analysed even though they have been observed to show strong 
association to T2D in existing literature [149, 181, 242]..  The variants identified in 
this study will perhaps give us some insight into the African genetic variation and its 
contribution to the nature of the disease. It is, however, important to note that for this 
study, it is assumed that the oldest human populations reside on the African 
continent and as a result have greater genetic variation than populations that have 
migrated out of Africa and have been through several bottle necks. In addition 
Khoisan admixture among many black African populations has further contributed to 
the genetic variation on the continent [243, 244]. 
Since the essence of this study was to identify not just variants that differ between 
Africa and other continents but variants that are also selected in Africa that could 
either confer a risk to or protect against T2D, it was important to see which of the 
differentiated genes had signatures of selection in the African populations. 
Signatures of selection were also sought for these genes in the European and Asian 
populations to ensure that patterns of selection seen in the African populations were 
indeed unique to, or different in, Africa and not duplicated in the non-African 
populations.  
The SNRPD1 gene encodes a small nuclear ribonucleoprotein (SNRNP) that can act 
as a charged protein scaffold to strengthen SNRNP-SNRNP interactions through 
nonspecific electrostatic contacts with RNA or just assist in the assembly of SNRNP 
[231, 245]. Its involvement has been proposed in the spliceosome pathway and the 
RNA splicing process [246].It is rather interesting to find an identical set of SNPs 
from the SNRPD1 gene showing signatures of selection in both the TSI and YRI 
populations whereas only a portion of these SNPs were selected in the LWK 
population. This is perhaps the result of gene flow as a consequence of one of the 
oldest population admixtures in sub-Saharan Africa in the central West African 
populations about 4,000 – 12,000 years ago. This migration into Africa from Eurasia 
occurred during a period when the Sahara desert was thought to have become 
green due to humid conditions [247]. This mixture probably resulted in independent 
adaptations in both populations as the direction of selection of the SNPs, based on 
positive and negative iHS scores, are the same. It is also important to note that in the 
investigation of differences between African and non-African genome, the extent of 
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admixture between Africans and Neanderthals and Denovisans is less than that 
observed in non-African genomes. It has been proposed that some selection has 
occurred for the Neanderthal contributions, for example in genomic regions that 
contain genes involved in lipid catabolism [248]. 
In terms of genetic distribution amongst populations in this analysis, only 1 of the 8 
differentiated SNRPD1 SNPs, rs2959527, was common to the 3 populations. This 
SNP was not in LD with any other SNP on the list of significantly differentiated SNPs 
or selected SNPs in the African populations. Of greater interest, however, is the 
SNP, rs2847139 that was selected only in an African population, LWK, and 
significantly differentiated from the non-African populations. The high LD observed 
between this SNP and 3 (rs2850568, rs2959525, rs3017641) other highly 
differentiated SNPs suggests a possible haplotype block in the SNRPD1 gene being 
considerably implicated in the pathogenesis of T2D. Although the SNRPD1 gene has 
not been previously associated with T2D in existing literature, the presence of 
SNRPD1 SNPs in the iHS results of both African populations as well as FST analysis 
results in this study perhaps present it as a novel candidate for further investigation 
with respect to T2D. With the knowledge that SNRPD1 features prominently in the 
spliceosome pathway [246], which happens to rank highly in the functional 
annotation results of the expression gene set, it is possible that alternative splicing of 
transcripts are  abnormally regulated as a result of a polymorphism in the gene 
leading to an increased risk of T2D development via an as yet unknown mechanism. 
It has been previously shown that the recognition of splicing sites is dependent on 
the protein composition of the spliceosome [249]. The spliceosome architecture 
could thus be altered by the dysregulated expression of a coding gene and 
consequently its splicing process which may have implications on different 
biochemical levels. A proinsulin gene splice variant has been previously 
demonstrated to increase the translation efficiency in human pancreatic islets [250]. 
Also, a number of obesity-related genes which may cause a predisposition to T2D 
such as Lipin 1(LPIN1), low density lipoprotein receptor (LDLR) and insulin receptor 
(INSR) are regulated by alternative splicing mechanisms [251–254]. Splicing factor, 
arginine/serine-rich 10 (transformer 2 homolog, Drosophila), SFRS10, known as 
transformer-2 protein homolog beta, TRA2B, in humans, is an RNA-splicing protein 
that has been shown to be down regulated in the muscle and liver of obese 
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individuals, This protein was demonstrated to help in the regulation of LPIN1, a key 
regulator of lipid metabolism [255]. It has also been proposed that a defective 
alternative splicing mechanism, can lead to a truncated less functional isoform in the 
TCF7L2 gene, the most strongly associated T2D gene to date [256]. This isoform is 
associated with elevated levels of serum free fatty acids and plasma glucose as well 
as with adipose tissue insulin resistance with consequences for T2D [251]. The 
overexpression of different lengths of TCF7L2 mRNA variants have also been 
demonstrated to have either protective effects on beta-cell function and survival or 
induced impaired insulin secretion and apoptosis in human islets [257, 258]. 
It is possible that the role of SNRPD1 in the spliceosome conferred it with a crucial 
regulatory role that has made it a candidate for selection. However, as its targets are 
yet to be characterized, it is difficult to make such speculations. Further studies to 
elucidate the regulatory pathways and SNRPD1-associated genes will very likely 
provide more insight and possibly uncover its functional significance. The emphasis 
of this section has been on some of the SNPs in the SNRPD1 gene and a possible 
mechanism of action via the spliceosome complex in suggesting its role in the 
pathogenesis of T2D in Africa. It is, however, necessary to guard against over 
interpretation of the results as it is difficult to speculate on whether the selection 
observed in this gene is as a result of a consequence of the disease or of 
predisposing factors that increase the risk of the development of T2D. Also, the 
inclusion of the intergenic SNPs in the downstream analyses would have arguably 
enriched the selection process, however, this was primarily a gene-centric approach. 
The aim of the study was to identify potentially novel population-specific gene-
associated variants in the queried African populations. The definition of novelty of 
SNPs for the scope of this research is the presence of SNPs in the queried African 
populations in the 1000 Genomes data set (Phase1, version 3, October 2012 
upload) that have not been previously identified in other populations. The majority of 
the SNPs in this upload had been assigned rsIDs such that the effect of the 
exclusion of SNPs without rsIDs would be minimal as only a small number of SNPs 
were excluded. However, it is also possible that the excluded SNPs may actually be 
potentially interesting candidate SNPs for T2D in Africans 
The computational approach employed in this study primarily reanalysed microarray 
raw data and incorporated the results of GWAS in the prioritization of T2D-relevant 
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genes and subsequently SNPs. Like in many other meta-analyses-focused studies, 
pathway memberships and gene ontologies were considered in the gene 
prioritization steps. However, the integration of the 1000 Genomes dataset in an 
attempt to retrieve possibly novel T2D-relavant SNPs in African populations had not 
been previously done. This study therefore presents the possibility of identifying 
potentially relevant disease-associated SNPs from existing data by utilizing curated 
databases to computationally make inferences from populations that were not 
involved in the original studies. 
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Figure 4.1 A schema of a possible relationship between the functional 
annotation terms from GWAS and microarray studies and the pathogenesis of 
T2D. Blue and red colours represent terms associated with GWAS and 
microarray studies respectively.  
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4.2 Conclusion 
The multi-factorial nature of type 2 diabetes complicates the elucidation of the 
aetiology of the disease. Beta-cell dysfunction and insulin resistance remain the two 
relative constant features in the development of T2D; however, there are multiple 
avenues and processes that could lead to these conditions. Different global 
environments can influence the epigenome, which regulates gene expression 
patterns, and contribute to varying extents to the development of the disease. For 
example, in T2D, diet and physical inactivity play a major role. It thus makes logical 
sense that the component of the disease where some measure of insight can be 
gained is in its genetics. Studies have shown that humans are about 99.9% 
genetically similar [259]. The ~0.1% variation, however, has proven to be quite 
consequential with respect to disease aetiology and appropriate treatment courses. 
This study attempted to take advantage of the similar clinical presentation of T2D 
across populations to hone in on the possible differences in the African nature of the 
disease as research has been extensive in non-African populations and T2D 
molecular research on the continent has been relatively minimal. The genetic 
differentiation observed, based on the FST analysis, of different sets of variants from 
those identified in other populations in genes that have been previously associated 
with T2D perhaps suggests that there is some specificity in T2D-susceptibility on the 
African continent. The selection and genetic differentiation of the SNRPD1 gene 
variants, which do not appear to have been previously associated with T2D in the 
literature, perhaps presents it as an interesting candidate in the pathogenesis of 
T2D, worth studying more intricately.  
It is important to note that the analysis approach and general workflow applied in this 
project that prioritized streamlining highly differentiated loci to those selected in the 
queried African populations may have eliminated the chance of  identifying other 
potential variants of interest in the pathogenesis of T2D, that are common across 
multiple continental populations. However, the main aim of this work was to identify 
those T2D-associated variants that show some level of specificity to the interrogated 
African populations to give us some possible insights into the pathogenesis of the 
disease on the continent. 
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Considering the prevalence projections for type 2 diabetes on the African continent 
and the current state of research efforts in the field, it would appear as though the 
future is rather bleak. It is anticipated, however, that proposed large scale research 
efforts on the continent like the Human Hereditary and Health in Africa consortium, 
H3Africa, will provide some insight not only to the African nature of the disease but 
also to identifying more of the missing heritability component in the pathogenesis of 
the disease. Elucidating some of the “African nature” of T2D would in the short term 
provide more appropriate continental information for chip design and in the long 
term, more targeted therapies to combat and possibly prevent the progression of the 
disease. 
4.2.1 Study Limitations 
 GWAS 
It is highly unlikely that the representation of the genome from most of the current 
GWA studies accurately capture the diversity present in African populations. It is, 
therefore, possible that potentially T2D-relevant variants may have been missed. 
 Gene expression studies 
It is known that the non-homogenous nature of the tissue samples (except in study 6 
where a laser capture was done) will affect the expression profiles of the genes. 
Also, the use of a similar analyses protocol on experiments with different hypotheses 
and questions, with the overarching aim of a ‘one-touch’ analysis pipeline, may have 
been too stringent in some of the studies. The sample sizes may have had an effect 
on the limma analysis results as some of the studies had rather small sample sizes. 
It will be worthwhile for the criteria for expression data deposition to be reviewed as 
some of the available data are rather inconsistent and the sample sizes rather small. 
It is also possible that differences in gene expression observed may not be related to 
polymorphisms within that gene but to polymorphisms in other genes that control the 
transcription of the index gene. 
 Study hypothesis 
It is possible that the use of non-African samples to retrieve African-specific 
information on T2D may have limited the outcome of this study as some genes might 
have been missed. The aim of the study was not to necessarily identify novel genes, 
but rather novel African-specific variants in existing genes. However, it is believed 
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that the clinical similarity in the presentation of the disease [260] gives some 
measure of validity to the study rationale. 
4.2.2 Future Directions  
The logical next step will be to test the results of this selection and analysis approach 
in a high risk group in Africa by genotyping the SNPs of interest from not only the 
SNRPD1 gene but also those from the 6 other highly differentiated genes. It would 
also be interesting to investigate the downstream targets of these genes in the 
tissues most affected by T2D. 
With the changing landscape of genomic science, it will be interesting to see what 
whole genome sequencing of type 2 diabetic individuals in Africa would highlight. 
Also, most of the GWAS performed to date have a bias in their experimental design 
as they generally detect susceptibility effects attributable to common SNPs. Thus, a 
more in-depth analysis of rare variants as well as copy number variants might 
provide some clues to the pathogenesis of T2D. 
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APPENDIX I – GWAS Genes and SNPs Lists 
GWAS Genes List 
MARCH1 CRY2 HUNK PCBP3 SLC30A8 
ABCB11 CSMD1 IDE PCK1 SLC44A3 
ACHE CTCFL IG2BP2 PCNXL2 SND1 
ADAM30 DCD IGF1 PCSK1 SNX7 
ADAMTS9 DGKB IGF2BP2 PDGFC SPRY2 
ADCY5 DPYSL5 IRS1 PDX1 SRR 
ADRA2A DUSP9 ITGB6 PEPD ST6GAL1 
AKAP2 F3 JAZF1 PEX5L SULF1 
AKAP6 FADS1 KCNJ11 PLS1 SYK 
ANK1 FAM58A KCNK16 PPARG SYN2 
AP3B1 FBXL10 KCNQ1 PPP1R3B TCERG1L 
AP3S2 FITM2 KCNU1 PPP2R2C TCERGIL 
ARAP1 FLJ16165 KIF11 PRC1 TCF2 
ARF5 FOXA2 KLF14 PRDM5 TCF7L2 
ATP10A FOXN3 LAMA1 PROX1 TGFBR3 
BARX2 FTO LARP6 PSMD6 THADA 
BCL11A G6PC2 LGR5 PTCHD3 TMEM163 
C14orf70 GALNTL4 LMO1 PTPRD TMEM195 
C2CD4A GAS1 LOC64673 PTTG1 TMEM45B 
C2CD4B GCC1 LOC72901 R3HDML TP53INP1 
C6orf57 GCK LOC729013 RASGRP1 TRIAP1 
CACNA1D GCKR LPIN2 RBM38 TSPAN8 
CAMK1D GLIS3 LYPLAL1 RBM43 TUBA3C 
CDC123 GRB10 MADD RBMS1 UHRF1BP1 
CDKAL GRB14 MAEA RHOU VEGFA 
CDKAL1 GRHL3 MAP3K1 RND3 VPS13C 
CDKN2A GRK5 MGC21675 RREB1 VPS26A 
CDKN2B HHEX MRPL33 SACS WFS1 
CENTD2 HLA-
DQA2 
MTNR1B SC4MOL WISP1 
CETN3 HMG1L1 NOTCH2 SEZ6L WWOX 
CHCHD9 HMG20A NXN SFMBT2 ZBED3 
CHL1 HMGA2 OR4S1 SGCG ZFAND3 
CMIP HNF1A PALM2 SGSM2 ZFAND6 
COBLL1 HNF1B PAX4 SLC10A6 ZMAT4 
CR2 HNF4A PCBP3 SLC2A2 ZPLD1 
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GWAS SNPs List 
rs10050311 rs2383208 rs7903146 rs5219 rs163182 rs10741243 rs4689388 
rs10229583 rs2501677 rs7944584 rs1111875 rs11642841 rs472265 rs2943641 
rs10248619 rs2714337 rs7981942 rs13266634 rs849134 rs3773506 rs6235 
rs10461617 rs2785980 rs8004664 rs9300039 rs231362 rs11677370 rs4502156 
rs10811661 rs2943634 rs8050136 rs7756992 rs243021 rs7630877 rs4790333 
rs10814916 rs308971 rs8090011 rs12304921 rs13292136 rs17045328 rs9727115 
rs10829848 rs328506 rs8182584 rs7659604 rs7578326 rs1048886 rs10838687 
rs10830963 rs340874 rs9552416 rs358806 rs4760790 rs7593730 rs10501320 
rs10849893 rs35747 rs9552911 rs9465871 rs11634397 rs4712523 rs1549318 
rs10885122 rs3736594 rs9841287 rs1495377 rs1552224 rs515071  
rs10886471 rs3802177 rs9939609 rs4607103 rs896854 rs1327796 
rs11041816 rs3916765 rs4506565 rs9472138 rs972283 rs10993738 
rs11165354 rs4402960 rs35767 rs7020996 rs10965250 rs7656416 
rs11257655 rs4430796 rs11071657 rs5215 rs10440833 rs4712524 
rs11558471 rs4527850 rs563694 rs6931514 rs13081389 rs6769511 
rs11603334 rs4607517 rs180730 rs17036101 rs1531343 rs2237897 
rs11605924 rs4646949 rs10510634 rs1153188 rs7957197 rs17584499 
rs11708067 rs4691380 rs7731657 rs10923931 rs1801214 rs391300  
rs11920090 rs4841132 rs2722425 rs7578597 rs4457053 rs2237895 
rs12010175 rs5015480 rs2166706 rs7961581 rs8042680 rs7018475 
rs13179048 rs560887 rs1387153 rs12779790 rs649891 rs2722769 
rs13273088 rs5945326 rs7043482 rs864745 rs1333051 rs7107217 
rs1334893 rs6048205 rs17589516 rs7901695 rs7305618 rs7560163 
rs1371614 rs623323 rs9792548 rs564398 rs730570 rs7542900 
rs1470579 rs6426514 rs1401492 rs10946398 rs1374910 rs6467136 
rs1483121 rs6670533 rs16962638 rs1436955 rs7119 rs6815464 
rs17046216 rs6723108 rs6576507 rs1359790 rs2833610 rs1535500 
rs17053082 rs7034200 rs2407314 rs10906115 rs2063640 rs17797882 
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rs174550 rs7173964 rs12655917 rs3923113 rs6583826 rs9470794 
rs1801282 rs7178572 rs4819143 rs16861329 rs9295474 rs3786897 
rs1895320 rs7403531 rs17431357 rs4812829 rs12027542 rs831571  
rs2191349 rs7607980 rs591044 rs2028299 rs10460009 rs6017317 
rs2237892 rs7754840 rs2407103 rs1802295 rs3792615 rs7041847 
rs2293941 rs7766070 rs6712932 rs7172432 rs642858 rs16955379 
rs2300835 rs780094 rs5219 rs1436953 rs7636 rs12518099 
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APPENDIX II – Expression Genes List 
SEPT6 ARPC2 CASP1 CLTC EMR1 GATAD1 HOXD1 
SEPT9 ASH2L CASP10 CMAHP ENG GATAD2
A 
HSP90B1 
ABCC10 ATP5B CASQ1 CNN2 ENSA GCFC1 HSPC072 
ABCF2 ATP5E CAT CNOT8 ENTPD3 GCNT1 HUWE1 
ACOT1 ATP5G2 CBX4 COG2 EPOR GFER ID2 
ACSL1 ATP6AP2 CC2D1A COX5A ERAP1 GIF IDE 
ACSL6 ATP6V1E
1 
CCDC15 CRIP1 ERCC4 GIT2 IDH3G 
ADAM28 ATP8B1 CCDC85
B 
CRYM ERGIC2 GK IDS 
ADIPOR2 ATXN2L CCPG1 CSNK2A
1 
ERH GLS IDUA 
ADNP2 AURKAIP
1 
CCR1 CSTF1 ERLIN1 GMFB IGHA1 
ADRB3 B4GALT5 CCR2 CTDSP2 EXOC7 GNAQ IKZF1 
AHCY BBIP1 CCR4 CUL4A EYA2 GNAS IQCB1 
AHSP BLCAP CD200 CYC1 F5 GOLGA1 IRF4 
AKR7A2 BLM CD7 CYP2B6 FABP5 GPHN ITFG1 
AKT2 BOP1 CDC123 DARS FABP7 GPS2 ITPR1 
AKT3 BRD2 CDC16 DARS2 FAM115
A 
GRB10 ITPR2 
ALPPL2 BTF3 CDC40 DBT FAM47E GRSF1 ITSN2 
ANAPC13 BTN1A1 CDC5L DCAF15 FAR2 GSN IVD 
ANKFY1 BTN2A1 CDK14 DHX15 FBXO11 GTF3C2 JTB 
ANKHD1 C11orf30 CDS2 DICER1 FBXO28 GZMM JUN 
ANP32A C12orf47 CEACAM
1 
DLG1 FBXO9 HCFC1R
1 
KCNAB1 
AP3B1 C14orf45 CEP350 DLX4 FCF1 HEATR1 KCNJ1 
APC C15orf44 CFDP1 EDEM3 FCGR2B HEXA KDM4A 
APOE C16orf42 CHN2 EDF1 FCGR2C HIRA KDM4C 
APOL2 C19orf60 CHPT1 EEF1D FHL1 HLA-
DPA1 
KHSRP 
ARF5 C1orf9 CHTOP EEF1E1 FKBP1A HMOX2 KIAA0125 
ARFIP1 C1QBP CIRBP EGR1 FLJ1129
2 
HNRNPA
0 
KIDINS22
0 
ARHGAP1
5 
C8orf33 CIZ1 EIF1 FOXC1 HNRNPA
3 
KLC1 
ARHGEF1 CACYBP CLCN4 EIF1AX FOXN3 HNRNPD KLF9 
ARHGEF1
2 
CALM1 CLK1 EIF4A3 FRY HNRNPK KRT33A 
ARHGEF7 CAPZB CLTB EIF4H GADD45
B 
HNRNPU LAMA4 
 
  
108 
 
LAMP1 MFN1 NF1 PEMT PTPRC RPL12 SNRPD1 
LAT MFNG NFIB PEX5 PTPRCA
P 
RPL14 SNRPE 
LEPRO
T 
MINK1 NOMO1 PFKM PVRL3 RPL35A SNX1 
LIMK1 MIOS NONO PGK1 QKI RPL7 SNX13 
LMBRD
1 
MLX NOP10 PGRMC2 RAB11FI
P2 
RTF1 SOCS5 
LMF1 MMP14 NOS1 PHKG1 RAB14 RUFY3 SON 
LPCAT
4 
MMP24 NPRL3 PHLPP2 RAB3GA
P2 
RWDD1 SORL1 
LSM12 MON2 NR2F2 PHTF1 RAB6A SAP130 SOX2 
LSM14
A 
MPHOSP
H6 
NR3C1 PICALM RABGGT
A 
SART1 SPO11 
LSM2 MPPE1 NR4A1 PIK3R4 RAD17 SCAMP1 SPOP 
LTBP4 MR1 NRG1 PML RALGDS SEC23B SRCAP 
LYST MRP63 NSF PMVK RANBP2 SECISBP
2L 
SRR 
LZTFL1 MRPL28 NTRK3 PNISR RASGRP
2 
SEMA3F SRRM1 
MAFB MRPL9 NUCB2 POLDIP3 RASSF7 SESN1 SRRM2 
MAN1A
2 
MRPS10 NUP98 POLG RBCK1 SETX SRSF1 
MAP4K
1 
MTDH NUPL1 POLR2B RBM3 SF1 SRSF9 
MAPR
E2 
MTF1 OSBP POM121L
1P 
RBM38 SF3A2 SSBP3 
MAST2 MTOR PAFAH1
B1 
PPIA RBMY1A
1 
SFI1 ST6GALNA
C4 
MAU2 MTRR PBX2 PPIB RC3H2 SFPQ STAU1 
MAZ MYL4 PCBP1 PPP1R2 RCC1 SFXN3 STK24 
MBD3 MYO7A PCBP2 PPPDE1 REST SLC25A1
7 
STRAP 
MCFD2 MZT2B PCDH9 PREPL RGS14 SLC2A4R
G 
STX16 
MCL1 NAA60 PCM1 PRKACA RGS4 SLC35A2 SULT1B1 
MDH2 NAMPT PCNX PRKAG1 RIN3 SLC39A4 SUMO1 
MEAF6 NBPF10 PDCD4 PRKCSH RNF126 SLC39A8 SUMO2 
MED16 NCL PDE10A PRPF31 RNF34 SLC7A4 SUMO3 
MED21 NCOA1 PDE4DIP PSMA2 RNGTT SLIRP SUPT4H1 
MED27 NCOR1 PDE8A PSMA3 RNPS1 SMAD3 TAF10 
MEF2A NDRG2 PDPK1 PSMD1 ROCK2 SMARCA
4 
TAF1C 
MEF2C NDUFA5 PEBP1 PTBP1 RPH3A SNF8 TANK 
MFAP3 NDUFB8 PEF1 PTPN12 RPL11 SNRNP70 TAOK2 
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TAP2 TROVE2 
TBC1D5 TTC12 
TBK1 U2AF2 
TCEB1 UBE2D2 
TCERG1 UBR2 
TCL6 UBR5 
TERF2IP UFM1 
TF USP34 
TFRC USP9X 
TGFB1 UTP14C 
TKT VAMP1 
TLR7 WDFY3 
TMBIM6 WIPI2 
TMEM30B WNK1 
TMF1 WSB1 
TMOD1 XAB2 
TNFRSF14 XRCC6 
TOB1 YBX1 
TOM1L1 YIPF6 
TOMM20 YTHDC2 
TOR1B YWHAE 
TOX3 YWHAZ 
TOX4 YY1 
TP63 ZC3HAV1 
TPI1 ZCCHC6 
TPM2 ZFP36L2 
TPR ZIC1 
TRAPPC2 ZNF10 
TRAPPC9 ZNF277 
TRIM2 ZNF287 
TRIM38 ZNF473 
TRIM44  
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APPENDIX III – Core “Genes List” (used for study analyses)  
ADAM30 GCK NOTCH2 SF1 
ADAMTS9 GCKR NR2F2 SF3A2 
ANKHD1 GPS2 NRG1 SFPQ 
ATP8B1 GRSF1 PAX4 SLC2A2 
BLM HEATR1 PCBP1 SLC30A8 
BOP1 HHEX PCBP2 SMAD3 
CACNA1D HNF1A PCK1 SMARCA4 
CAMK1D HNF1B PCSK1 SNRNP70 
CBX4 HNF4A PDCD4 SNRPD1 
CCDC85B HNRNPA0 PDX1 SNRPE 
CDC123 HNRNPA3 PEBP1 SOX2 
CDC16 HNRNPD PML SPOP 
CDC40 HNRNPK POLR2B SRRM1 
CDC5L HNRNPU PPARG SRRM2 
CDKAL1 ID2 PROX1 STRAP 
CDKN2A IDE PRPF31 SUMO1 
CDKN2B IGF1 PSMA2 SUPT4H1 
CRYM IGF2BP2 PSMA3 SYN2 
CSTF1 IKZF1 PSMD1 TCERG1 
DCD IRS1 PTBP1 TCF7L2 
DHX15 JAZF1 PTPRC TERF2IP 
DICER1 JUN QKI TGFB1 
EGR1 KCNJ11 RAD17 THADA 
EIF4A3 KHSRP RBM3 TP63 
ENG KIF11 RBM38 TRIAP1 
ERCC4 LGR5 RBMY1A1 TSPAN8 
F3 LSM2 REST U2AF2 
FADS1 MAEA RNGTT UTP14C 
FCF1 MBD3 RNPS1 VEGFA 
FKBP1A MEF2C RPL11 WFS1 
FOXA2 MLX RPL14 XAB2 
FOXN3 MTDH RPL35A YBX1 
FTO NCOR1 RPL7 YWHAE 
GAS1 NONO SART1 ZCCHC6 
GATAD2A NOP10 SETX ZFP36L2 
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APPENDIX IV – List of Genes in the Intercontinental Comparisons with FST ≥ 0.25 
(63 genes) and the final list of FST genes (7 genes) and SNPs (228 SNPs) 
AFR_nonAFR – Genes (FST ≥ 0.25) 
Gene SNP 
Count 
 Gene SNP 
Count 
ADAM30 1  JAZF1 1 
ADAMTS9 18  KIF11 20 
ANKHD1 3  LGR5 38 
ATP8B1 12  MLX 1 
BLM 6  NCOR1 1 
BOP1 5  NOTCH2 25 
CACNA1D 26  NR2F2 4 
CAMK1D 49  NRG1 45 
CDC16 4  PPARG 35 
CDC40 3  PTBP1 2 
CDKAL1 22  QKI 24 
CDKN2A 1  RBM38 20 
CDKN2B 1  RNGTT 146 
CRYM 4  RNPS1 3 
CSTF1 1  RPL35A 4 
ENG 8  SART1 5 
ERCC4 6  SF1 3 
FCF1 2  SFPQ 1 
FOXA2 1  SLC2A2 1 
FOXN3 25  SLC30A8 23 
FTO 37  SNRPD1 9 
GATAD2A 1  STRAP 4 
GRSF1 7  SYN2 26 
HEATR1 15  TCF7L2 10 
HNF1B 8  TERF2IP 9 
HNRNPA3 1  THADA 22 
HNRNPD 2  TP63 14 
ID2 2  TSPAN8 11 
IDE 1  U2AF2 1 
IGF2BP2 27  WFS1 3 
IKZF1 1  YWHAE 12 
   ZFP36L2 1 
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AFR_nonAFR – SNPs and Genes (FST ≥ 0.25, p ≤ 0.05, overrepresentation score 
≥ 2) 
SNP Gene  SNP Gene 
rs11907421 RBM38  rs201153006 RNGTT 
rs2426714 RBM38  rs201553456 RNGTT 
rs3764719 RBM38  rs2026019 RNGTT 
rs3764722 RBM38  rs2064632 RNGTT 
rs6014986 RBM38  rs2149459 RNGTT 
rs6014987 RBM38  rs2149460 RNGTT 
rs6014988 RBM38  rs2181024 RNGTT 
rs6025526 RBM38  rs2610705 RNGTT 
rs6025527 RBM38  rs2610706 RNGTT 
rs6025528 RBM38  rs2610707 RNGTT 
rs6025529 RBM38  rs2610709 RNGTT 
rs6025530 RBM38  rs2610710 RNGTT 
rs6025531 RBM38  rs2610712 RNGTT 
rs6025532 RBM38  rs2610714 RNGTT 
rs6025533 RBM38  rs2610716 RNGTT 
rs6025537 RBM38  rs2610717 RNGTT 
rs6025541 RBM38  rs2610718 RNGTT 
rs6099605 RBM38  rs2610719 RNGTT 
rs6128020 RBM38  rs2610720 RNGTT 
rs7264925 RBM38  rs2610721 RNGTT 
rs111904268 RPL35A  rs2610723 RNGTT 
rs61215870 RPL35A  rs2610724 RNGTT 
rs7631002 RPL35A  rs2610726 RNGTT 
rs9818493 RPL35A  rs2610728 RNGTT 
rs1011591 RNGTT  rs2610729 RNGTT 
rs1321085 RNGTT  rs2610730 RNGTT 
rs143448457 RNGTT  rs2610732 RNGTT 
rs148728841 RNGTT  rs2610733 RNGTT 
rs149726691 RNGTT  rs2610736 RNGTT 
rs1590253 RNGTT  rs2610744 RNGTT 
rs1928064 RNGTT  rs2610746 RNGTT 
rs1928065 RNGTT  rs2610747 RNGTT 
rs199533287 RNGTT  rs2610749 RNGTT 
rs200127482 RNGTT  rs2610751 RNGTT 
rs200217831 RNGTT  rs2610752 RNGTT 
rs200515942 RNGTT  rs2610753 RNGTT 
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SNP Gene  SNP Gene 
rs2610754 RNGTT  rs2756398 RNGTT 
rs2610755 RNGTT  rs2756399 RNGTT 
rs2610756 RNGTT  rs2756400 RNGTT 
rs2610758 RNGTT  rs2756401 RNGTT 
rs2610759 RNGTT  rs2756403 RNGTT 
rs2610760 RNGTT  rs2756404 RNGTT 
rs2610761 RNGTT  rs2756405 RNGTT 
rs2610767 RNGTT  rs2756407 RNGTT 
rs2756348 RNGTT  rs2756408 RNGTT 
rs2756349 RNGTT  rs2756409 RNGTT 
rs2756350 RNGTT  rs2756410 RNGTT 
rs2756351 RNGTT  rs2756411 RNGTT 
rs2756353 RNGTT  rs2756412 RNGTT 
rs2756355 RNGTT  rs2756413 RNGTT 
rs2756357 RNGTT  rs2756414 RNGTT 
rs2756360 RNGTT  rs34693837 RNGTT 
rs2756361 RNGTT  rs35095368 RNGTT 
rs2756362 RNGTT  rs35792075 RNGTT 
rs2756363 RNGTT  rs36063561 RNGTT 
rs2756364 RNGTT  rs36112710 RNGTT 
rs2756369 RNGTT  rs3839421 RNGTT 
rs2756377 RNGTT  rs56277084 RNGTT 
rs2756379 RNGTT  rs57988674 RNGTT 
rs2756381 RNGTT  rs58588716 RNGTT 
rs2756383 RNGTT  rs60138176 RNGTT 
rs2756384 RNGTT  rs66869054 RNGTT 
rs2756385 RNGTT  rs67781583 RNGTT 
rs2756386 RNGTT  rs6902454 RNGTT 
rs2756388 RNGTT  rs6915642 RNGTT 
rs2756389 RNGTT  rs6919539 RNGTT 
rs2756390 RNGTT  rs6919725 RNGTT 
rs2756391 RNGTT  rs6920037 RNGTT 
rs2756392 RNGTT  rs71554791 RNGTT 
rs2756393 RNGTT  rs71661540 RNGTT 
rs2756394 RNGTT  rs71681491 RNGTT 
rs2756395 RNGTT  rs76042624 RNGTT 
rs7739245 RNGTT  rs2493410 NOTCH2 
rs7747388 RNGTT  rs2493416 NOTCH2 
rs7750038 RNGTT  rs2493419 NOTCH2 
rs7759650 RNGTT  rs2641316 NOTCH2 
rs7760061 RNGTT  rs2793830 NOTCH2 
rs7760588 RNGTT  rs327197 NOTCH2 
rs7760910 RNGTT  rs4659250 NOTCH2 
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rs79967308 RNGTT  rs5025718 NOTCH2 
rs911596 RNGTT  rs56216048 NOTCH2 
rs9344843 RNGTT  rs6688004 NOTCH2 
rs9344844 RNGTT  rs67062239 NOTCH2 
rs9351171 RNGTT  rs699780 NOTCH2 
rs9353583 RNGTT  rs7414396 NOTCH2 
rs9353592 RNGTT  rs7530844 NOTCH2 
rs9353633 RNGTT  rs835574 NOTCH2 
rs9362538 RNGTT  rs11187085 KIF11 
rs9362539 RNGTT  rs112853133 KIF11 
rs9444639 RNGTT  rs11815573 KIF11 
rs9444650 RNGTT  rs11817621 KIF11 
rs9451046 RNGTT  rs12259474 KIF11 
rs9451053 RNGTT  rs12261518 KIF11 
rs9451062 RNGTT  rs12264712 KIF11 
rs9451065 RNGTT  rs144328956 KIF11 
rs9451067 RNGTT  rs56111269 KIF11 
rs9451108 RNGTT  rs58045955 KIF11 
rs975973 RNGTT  rs59877288 KIF11 
rs10494235 NOTCH2  rs61011943 KIF11 
rs10923926 NOTCH2  rs6583828 KIF11 
rs10923929 NOTCH2  rs6583831 KIF11 
rs1493694 NOTCH2  rs7069680 KIF11 
rs1493695 NOTCH2  rs7070990 KIF11 
rs2364166 NOTCH2  rs7079583 KIF11 
rs2453042 NOTCH2  rs7079602 KIF11 
rs2453044 NOTCH2  rs7089765 KIF11 
rs2453055 NOTCH2  rs7914248 KIF11 
rs2453056 NOTCH2  rs2847117 SNRPD1 
rs2847139 SNRPD1 
rs2850556 SNRPD1 
rs2850558 SNRPD1 
rs2850568 SNRPD1 
rs2959525 SNRPD1 
rs2959527 SNRPD1 
rs3017641 SNRPD1 
rs34202260 SNRPD1 
rs142499350 NR2F2 
rs2398260 NR2F2 
rs73471288 NR2F2 
rs73471290 NR2F2 
  
 
